Login / Registration
 Set password
 Link to registration
  • Home
  • Videos
  • Committees
  • Program
    • Keynote speaker
  • Certificates and CME
  • Contact
  • Home
  • Videos
  • Committees
  • Program
    • Keynote speaker
  • Certificates and CME
  • Contact

Program

CME accreditation has been applied for with the Schleswig-Holstein State Medical Association.

PDF-Program-Booklet
Keynote Speaker
Conference Topics

• Pancreatic cancer - experimental and clinical
• Pancreatitis - acute and chronic
• Pancreatic surgery - minimally invasive and conventional
• Endoscopy and ultrasound
• Endocrine pancreas - diabetes mellitus, islet cells

• Pancreatic neuroendocrine neoplasms (pNEN)
• Pancreas - development and stem cells
• Cystic neoplasia of the pancreas
• Registries, biobanking, epidemiology and biostatistics in pancreatology

• Clinical studies in pancreatology - concepts, ongoing studies and results
• Pancreatology worldwide
• Science slam - clinical case presentations
• Science slam - experimental and biostatistical methods in pancreatology

Program Details
Search for names or keywords can be used. All times are CET.
09:30 - 12:30
09:30 - 12:30Workshop Room
Workshop 1: Robotic Pancreatic Surgery
In this this workshop, robotic pancreatic surgery will be introduced in detail by renowned experts in the field.One focus will be on the techniques of pancreatic and the biliary anastomosis. Another special topic will be intraoperative pitfalls and troubleshooting techniques.
Workshop Room
Robotic Pancreatojejunostomy in Blumgart Technique
Tobias Keck
Robotic Hepaticojejunostomy
Dirk Bausch
Pitfalls and Management in Robotic Pancreatic Surgery
Ugo Boggi
09:30 - 12:30
09:30 - 12:30Workshop Room
Workshop 2: Endoscopy and Endosonography in Pancreatic Disease
In this workshop, endoscopy in diagnosis and treatment of pancreatic disease will be highlighted. Experts will demonstrate cutting edge techniques and complex cases, with scientific background information.
Workshop Room
Endoscopy and Endosonography in Pancreatic Disease
Martha Kirstein
Endoscopy and Endosonography in Pancreatic Disease
Jens Marquardt
Endoscopy and Endosonography in Pancreatic Disease
Torsten Voigtländer
Endoscopy and Endosonography in Pancreatic Disease
Thomas von Hahn
Endoscopy and Endosonography in Pancreatic Disease
Johannes W. Rey
Endoscopy and Endosonography in Pancreatic Disease
Thomas Ewers
Endoscopy and Endosonography in Pancreatic Disease
Carsten Engelke
09:30 - 12:30
09:30 - 12:30Workshop Room
Workshop 3: Molecular Tumorboard and Biobanking in Pancreatic Cancer
Personalised therapy relying on molecular traits of individual tumors and patients is most likely the future of cancer therapy. Multimodal therapy is evolving in pancreatic cancer. Biobanks provide the basis for acquisition of biological samples with clinical annotation. In combination with sophisticated bioinformatic analysis, these provide the framework for clinical application of cutting edge targeted therapy in pancreatic cancer. This workshop will focus on molecular targeted therapy in pancreatic cancer and administrative, legal and financial aspects of molecular tumor boards, biobanks and bioinformatic analysis.
Workshop Room
Molecular Tumor Board: Technical and Legal Requirements
Nicolas von Bubnoff
Biobanking: Technical and Legal Requirements
Jens Habermann
Molecular Tumor Board: Bioinformatic Analysis
Hauke Busch
PDAC Cases from the Molecular Tumor Board
Nicolas von Bubnoff
Liquid Biopsy and Proteomics in Pancreatic Disease
Timo Gemoll
Further Topics
Stephanie Fliedner, Anke Fähnrich and Niklas Gebauer
09:30 - 12:30
09:30 - 12:30Workshop Room
Workshop 4: Ex Vivo Tissue Culture and Primary Cell Culture in Pancreatic Cancer
Ex vivo tissue culture and primary cell culture are have been rediscovered as in vitro models of pancreatic cancer biology and drug treatment, and are undergoing rapid evolution. This workshop will demonstrate the techniques of ex vivo tissue culture and primary cell culture, as well as knowledge of the logistic and legal aspects that are needed to set up a prospective in vitro culture program.
Workshop Room
Ex Vivo Tissue Slide Culture
Rüdiger Braun
Primary Cell Culture
Darko Castven
10:30 - 12:30
10:30 - 12:30Meeting Room
Scandinavian Baltic Pancreas Club (SBPC): Forum of Excellence
Chairs: Asbjørn Mohr Drewes, Matthias Löhr
Meeting Room
10:30
10:30
The SBPC Forum of Excellence
Matthias Löhr
10:40
10:40
Presentation of Database Structure
Jakob Lykke Poulsen
10:55
10:55
Highlights of Scientific Work
Søren Schou Olesen
11:25
11:25
Break
11:40
11:40
Highlights of Scientific Work
Jens Brøndum Frøkjær
12:10
12:10
New Database Structure and Legal Aspects
Asbjørn Mohr Drewes
12:20
12:20
Other Outcomes of the Expert Forum
Asbjørn Mohr Drewes
12:30 - 13:30
12:30 - 13:30Exhibition Hall
Please visit the Industrial Exhibition
Please visit the Industrial Exhibition
Exhibition Hall
13:30 - 14:00
13:30 - 14:00Lecture Hall
Welcome Session and Greetings
Lecture Hall
14:00 - 14:20
14:00 - 14:20Lecture Hall
Walter Halangk Memorial Lecture
Chair: Robert Jaster
Lecture Hall
14:00
14:00
Keynote: Stem cells in Pancreatic Cancer
Alexander Kleger
14:20 - 15:30
14:20 - 15:30Lecture Hall
Presidental Session
Chairs: Tobias Keck, Ulrich Wellner, Jan D'Haese, Georg Beyer
Lecture Hall
14:20
14:20
50 Years of Pancreatic Surgery - First Hand Experience
Andrew Warshaw
14:55
14:55
Development of Pancreatic Surgery in Moscow
Alexey Shabunin
15:30 - 15:50
15:30 - 15:50Exhibition Hall
Break
Please visit the Industrial Exhibition
Exhibition Hall
15:50 - 16:40
15:50 - 16:40Lecture Hall
Session I: Pancreatology - Clinical and Translational
Chairs: Ulrich Wellner, Louisa Bolm
Lecture Hall
15:50
15:50
Multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment  (ID 521)
Chiara Falcomatà, Stefanie Bärthel, Sebastian Widholz, Christian Schneeweis, Albulena Toska, Roland Rad, Marc Schmidt-Supprian, Günter Schneider, Dieter Saur, Jonathan Swietlik, Felix Meissner
16:05
16:05
Award ceremony Nordmark
Kevin Sander
16:10
16:10
Dynamics of the microbiome to pancreatic cancer from inception to invasion  (ID 409)
Nina Pfisterer, Christoph Ammer-Herrmenau, Volker Ellenrieder, Shiv Singh, Elisabeth Hessmann, Albrecht Neesse
16:25
16:25
High-risk Pancreatic Anastomosis vs. Total Pancreatectomy after Pancreatoduodenectomy: Postoperative Outcomes and Quality of Life Analysis  (ID 269)
Anna Burelli, Giovanni Marchegiani, Giampaolo Perri, Fabio Zoccatelli, Stefano Andrianello, Claudio Luchini, Katia Donadello, Claudio Bassi, Roberto Salvia
16:40 - 16:55
16:40 - 16:55Lecture Hall
Flash-Talks of selected posters (P1 - P60)
Chairs: Ulrich Wellner, Louisa Bolm
Lecture Hall
16:44
16:44
Flash Talk: The number of examined lymph nodes, and not only the lymph node involvement, influences survival in resected pancreatic ductal adenocarcinoma  (ID 323 | P5)
Rüdiger Göß, Carsten Jäger, Julie Perinel, Ilaria Pergolini, Elke Demir, Okan Safak, Florian Scheufele, Stephan Schorn, Mustapha Adham, Helmut Friess, Ekin Demir
16:45
16:45
Flash Talk: Phenotypic and molecular characterization of duct- and acinar-derived pancreatic ductal adenocarcinoma  (ID 341 | P44)
Jingxiong Hu, Yuanyuan Yu, Kathleen Schuck, Christoph Michalski, Andre Mihaljevic, Bo Kong
16:46
16:46
Flash Talk: Deciphering the role of the EZH2 epigenetic factor in ATM-deficient pancreatic cancer progression  (ID 364 | P34)
Elodie Roger, Luise Goldfuß, Johann Gout, Lukas Perkhofer, Thomas Seufferlein, Alexander Kleger, Elisabeth Heßmann
16:47
16:47
Flash Talk: Characterization of p53-status dependent EZH2 Activity in Pancreatic Cancer Progression and Treatment  (ID 418 | P37)
Lennart Versemann, Shilpa Patil, Zhe Zhang, Waltraut Kopp, Christin Kellner, Volker Ellenrieder, Elisabeth Hessmann
16:48
16:48
Flash Talk: The porcine urinary bladder mimics a pancreatic niche and enables cancer modelling  (ID 440 | P53)
Michael Karl Melzer, Markus Breunig, Frank Arnold, Felix Wezel, Anca Azoitei, Elodie Roger, Jana Krüger, Jessica Merkle, Lena Schütte, Friedemann Zengerling, Ninel Azoitei, Thomas Seufferlein, Meike Hohwieler, Christian Bolenz, Cagatay Günes, Johann Gout, Alexander Kleger
16:49
16:49
Flash Talk: Surgical treatment of complicated pseudocysts of the pancreas  (ID 474 | P9)
Igor A. Kryvoruchko
16:50
16:50
Flash Talk: Laparoscopic Peng’s Binding Pancreaticojejunostomy after Laparoscopic Wipple Prosedure  (ID 478 | P10)
Gurbankhan Muslumov, Gunay Aliyeva, Natig Zeynalov, Vugar Behbudov
16:51
16:51
Flash Talk: Early Surgery for Chronic Pancreatitis  (ID 484 | P19)
Iurii Mikheiev, Volodymyr Yareshko, Oleh Shpylenko, Dmytro Riazanov
16:52
16:52
Flash Talk: Perioperative Therapy Concepts in Pancreatic Cancer - A Cross-Validation Of Two National Registries  (ID 491 | P6)
Natalie Petruch, Louisa Bolm, Sergii Zemskov, Maria Zeller, Taisuke Baba, Jorge Roldan, Jon M. Harrison, Hiroki Sato, Ekaterina Petrova, Hryhoriy Lapshyn, Rüdiger Braun, Kim C. Honselmann, Richard Hummel, Oleksii Dronov, Alexander Kirichenko, Monika Klinkhammer-Schalke, Kees Kleihus-van Tol, Sylke Zeissig, Dirk Rades, Tobias Keck, Carlos Fernandez-del Castillo, Ulrich F. Wellner, Rodney E. Wegner
16:55 - 17:50
16:55 - 17:50Poster Room
Poster Lounge 1
Chair: Tim Glowka
Poster Room
16:55
16:55
Pancreatitis – Microbiome As Predictor of Severity (P-MAPS): A prospective international multicentre translational study   (P1 | ID 284)
Christoph Ammer-Herrmenau, Thomas Asendorf, Soeren Buchholz, Silke Cameron, Fabian Frost, Antonio Gomes, Robert Henker, Albrecht Hoffmeister, Lukasz Nawacki, Arpád Panyko, Veit Phillip, Sebastian Rasch, Simon Sirtl, Mark Weingarten, Julia Woitalla, Volker Ellenrieder, Albrecht Neesse
17:00
17:00
Patient-reported outcomes three months after pancreatic surgery – a first interim analysis of the German multicenter prospective PS-PROM trial  (P2 | ID 530)
Meike ten Winkel, Hussein Salama, Orlin Belyaev, Kai Timrott, Dennis Kleine-Döpke, Stefanie Rähder-Johnson, Holger Meisel, Felix Rückert, Schaima Abdelhadi, Kim C. Honselmann, Rüdiger Braun, Steffen Deichmann, Hryhoriy Lapshyn, Tobias Keck, Ulrich F. Wellner, Louisa Bolm
17:05
17:05
The Technology of Organ-Saving Endo-Laparoscopic Operations for Uncomplicated Cholecystolithiasis and Gallbladder Polyps  (P4 | ID 488)
Boris Shevchenko, Oleksandr Babii, Iryna Konenko
17:10
17:10
The number of examined lymph nodes, and not only the lymph node involvement, influences survival in resected pancreatic ductal adenocarcinoma  (P5 | ID 323)
Rüdiger Göß, Carsten Jäger, Julie Perinel, Ilaria Pergolini, Elke Demir, Okan Safak, Florian Scheufele, Stephan Schorn, Mustapha Adham, Helmut Friess, Ekin Demir
17:15
17:15
Perioperative Therapy Concepts in Pancreatic Cancer - A Cross-Validation Of Two National Registries  (P6 | ID 491)
Natalie Petruch, Louisa Bolm, Sergii Zemskov, Maria Zeller, Taisuke Baba, Jorge Roldan, Jon M. Harrison, Hiroki Sato, Ekaterina Petrova, Hryhoriy Lapshyn, Rüdiger Braun, Kim C. Honselmann, Richard Hummel, Oleksii Dronov, Alexander Kirichenko, Monika Klinkhammer-Schalke, Kees Kleihus-van Tol, Sylke Zeissig, Dirk Rades, Tobias Keck, Carlos Fernandez-del Castillo, Ulrich F. Wellner, Rodney E. Wegner
17:20
17:20
Protein-profiling of liquid biopsies for the differential diagnosis of pancreatic diseases  (P7 | ID 513)
Thao Vi Nguyen, Thorben Sauer, Kim C. Honselmann, Rüdiger Braun, Katharina Kern, Michael Kohl, Ulrich Wellner, Timo Gemoll
17:25
17:25
Second Line and Third Line Therapy with Nanoliposomal Irinotecan (nal-IRI) in pancreatic cancer: A Single Center Experience  (P8 | ID 531)
Maria Angeles Gonzalez-Carmona, Alexandra Bartels, Freddy Jose Frontado-Graffe, Christian Möhring, Farsaneh Sadeghlar, Taotao Zhou, Robert Mahn, Milka Marinova, Marieta Toma, Georg Feldmann, Peter Brossart, Tim Glowka, Jörg C. Kalff, Christian P. Strassburg
17:30
17:30
Surgical treatment of complicated pseudocysts of the pancreas  (P9 | ID 474)
Igor A. Kryvoruchko
17:35
17:35
Laparoscopic Peng’s Binding Pancreaticojejunostomy after Laparoscopic Wipple Prosedure  (P10 | ID 478)
Gurbankhan Muslumov, Gunay Aliyeva, Natig Zeynalov, Vugar Behbudov
17:40
17:40
Immunotherapy in pancreatic cancer: Effective adjuvant immunotherapy with ipilimumab and nivolumab in patient with microsatellite instability.  (P10a ID 551)
Koray Bozkurt, Steffen Deichmann, Louisa Bolm, Kim Christin Honselmann, Rüdiger Braun, Tobias Keck, Ulrich Wellner
16:55 - 17:50
16:55 - 17:50Poster Room
Poster Lounge 2
Chair: Florian Gebauer
Poster Room
16:55
16:55
Open-Label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy with Liposomal Irinotecan Combined with Oxaliplatin and 5 Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patients with Hepatic Oligometastatic Adenocarcinoma of the Pancreas (HOLIPANC)  (P11 | ID 546)
Florian Gebauer
17:00
17:00
The gender factor in pancreatic surgery: Are females less susceptible to complications?  (P12 | ID 547)
Florian Gebauer
17:05
17:05
Active smokers show ameliorated delayed gastric emptying after pancreatoduodenectomy  (P13 | ID 286)
Jana Enderes, Jessica Teschke, Martin von Websky, Steffen Manekeller, Jörg C. Kalff, Tim R. Glowka
17:10
17:10
Obesity does not influence delayed gastric emptying following pancreatoduodenectomy  (P14 | ID 399)
Jana Enderes, Jessica Teschke, Steffen Manekeller, Jörg C. Kalff, Tim R. Glowka
17:15
17:15
Climate change and its influence on the perioperative morbidity in pancreatic surgery - a heating problem  (P15 | ID 480)
Florian Oehme, Felix von Bechtolsheim, Sebastian Hempel, Christian Teske, Olga Radulova-Mauersberger, Marius Distler, Jürgen Weitz, Christoph Kahlert
17:20
17:20
Lipasemia in COVID-19-related ARDS  (P16 | ID 540)
Johanna Erber, Sebastian Rasch, Alexander Herner, Roland M. Schmid, Wolfgang Huber, Tobias Lahmer
17:25
17:25
Loss of muscle mass and strength in experimental chronic pancreatitis   (P17 | ID 376)
Julia Doller, Matthias Sendler, Frank U. Weiß, Mats L. Wiese, Jens Fielitz, Mihaela Delcea, Solvig Görs, Cornelia C. Metges, Luise Ehlers, Karen Bannert, Robert Jaster, Georg Lamprecht, Markus M. Lerch, Ali A. Aghdassi
17:30
17:30
Progressive intra-abdominal hypertension in the initial stage of acute pancreatitis worsens its prognosis  (P18 | ID 449)
Ivanna Shchyhel, Olexii Dronov, Inna Kovalska, Andrii Horlach, Fedir Prytkov, Ivanets Tetiana
17:35
17:35
Early Surgery for Chronic Pancreatitis  (P19 | ID 484)
Iurii Mikheiev, Volodymyr Yareshko, Oleh Shpylenko, Dmytro Riazanov
17:40
17:40
Bile acids modulate severity of acute pancreatitis depending on their hydrophobicity  (P20 | ID 532)
Quang Trung Tran, Matthias Sendler, Ulrich Weiss , Julia Doller, Mats Wiese , Michael Lalk , Uwe Bornscheuer , Markus Lerch, Ali Aghdassi
16:55 - 17:50
16:55 - 17:50Poster Room
Poster Lounge 3
Chair: Franco Fortunato
Poster Room
16:55
16:55
Propofol in pancreatic cancer surgery: No evidence for its impact on recurrence-free and overall survival  (P21 | ID 537)
Florian Oehme, André Michalski, Felix von Bechtolsheim, Torsten Richter, Christoph Kahlert
17:00
17:00
Preoperative Ultrasound Elastography (SWE) predicts increased risk of Pancreatic Fistula (POPF) after Pancreaticoduodenectomy   (P22 | ID 541)
Viktor von Ehrlich-Treuenstätt, Matthias Ilmer, Dirk Clevert, Frederik Klauschen, Steffen Ormanns, Hanno Niess, Jan D'Haese, Martin Angele, Jens Werner, Bernhard Renz
17:05
17:05
Primary patient-derived cell lines of pancreatic ductal adenocarcinoma (PDAC) as preclinical model for intratumor heterogeneity and treatment response  (P23 | ID 490)
Jessica Watzelt, Olha Lapshyna, Maren Drenckhan, Kim Christin Honselmann, Timo Gemoll, Tobias Keck, Ulrich Friedrich Wellner, Hendrik Ungefroren, Rüdiger Braun
17:10
17:10
CDKN2A-Mutated Pancreatic Ductal Organoids from Induced Pluripotent Stem Cells to Model a Cancer Predisposition Syndrome  (P24 | ID 506)
Meike Hohwieler, Jessica Merkle, Markus Breunig, Maximilian Schmid, Chantal Allgöwer, Alexander Kleger
17:15
17:15
The trend of pancreatic cancer in Brazil: 8-year analysis overview  (P25 | ID 507)
Bruna Oliveira Trindade, Gabriela Rangel Brandão
17:20
17:20
Influence of GSK3b on the regulation of DNA damage repair mechanisms in PDAC  (P26 | ID 519)
Geske Elisabeth Schmidt, Kristina Reutlinger, Aiko Johannes Bockelmann, Karly Conrads, Feda Hamdan, Umair Latif, Elisabeth Tan, Sercan Mercan, Marius Brunner, Hanibal Bohnenberger, Gabriela Salinas-Riester, Philipp Ströbel, Elisabeth Hessmann, Steven Arthur Johnsen, Volker Ellenrieder
17:25
17:25
Identification of molecular signatures for response of pancreatic ductal adenocarcinoma to chemotherapeutic agents for therapy stratification using clonal cell culture models  (P27 | ID 528)
Benedikt Färber, Kira M. Bichmann, Olha Lapshyna, Timo Gemoll, Thorben Sauer, Hendrik Ungefroren, Tobias Keck, Ulrich Wellner, Rüdiger Braun
17:30
17:30
Selective elimination of cancer stem cells as therapy for PDAC using novel dual BET/HDAC inhibitor TW09   (P29 | ID 543)
Kanishka Tiwary, Arijan Valar, Selina Mader, Stefanie Hauff, Tabea Dittrich, Xin Zhang, Eva Rodriguez-Aznar, Alexander Kleger, Thomas Seufferlein, Bruno Sainz Jr, Jens T. Siveke, Karolin Walter, Patrick C. Hermann
17:35
17:35
Antibiotic resistence patterns of bacterial bile cultures during pancreatic surgery – A single center analysis and systematic review  (P30 | ID 524)
Benjamin Müssle, Felix Bechtolsheim, Carolin Marx, Florian Oehme, Sebastian Hempel, Andreas Bogner, Christoph Kahlert, Marius Distler, Jürgen Weitz, Thilo Welsch
17:40
17:40
Identification of the Neurokinin-1 Receptor as targetable strat-ification factor for drug repurposing in Pancreatic Cancer  (P40 | ID 476)
Iris Beirith, Bernhard W. Renz, Shristee Mudusetti, Natalja S. Ring, Julian Kolorz, Dominik Koch, Alexandr V. Bazhin, Michael Berger, Jing Wang, Martin K. Angele, Jan G. D'Haese, Markus O. Guba, Hanno Niess, Joachim Andrassy, Jens Werner, Matthias Ilmer
16:55 - 17:50
16:55 - 17:50Poster Room
Poster Lounge 4
Chair: Maximilian Reichert
Poster Room
16:55
16:55
Characterization of therapeutic strategies for the treatment of ARID1A-deficient pancreatic cancer  (P31 | ID 314)
Maira Volland, Theresa Waßmann, Maria Ulisse, Zhe Zhang, Lennart Versemann, Jessica Spitalieri, Katherina Ewers, Matthias Dobbelstein, Shiv K. Singh, Laura Urbach, Lukas Klein, Elisabeth Hessmann
17:00
17:00
Chronic Lipopolysaccharide exposure promotes KrasG12D-induced pancreatic carcinogenesis  (P32 | ID 326)
Zhenhua Huang, Frank Bergmann, John Neoptolemos, Thilo Hackert, Franco Fortunato
17:05
17:05
An in ovo system to study tumor morphogenesis and metastatic dissemination of pancreatic cancer patient-derived organoids  (P33 | ID 329)
Raphela Ranjan, Katja Steiger, Roland Schmid, Maximilian Reichert
17:10
17:10
Proteome Biology of the Residual PDAC Tumor Mass after Neo-adjuvant Treatment: Comparing Chemo- and combined Chemo-radiation Therapy  (P35 | ID 377)
Maren Stillger, Sylvia Timme-Bronsert, Peter Bronsert, Martin Werner, Laura Tang, Oliver Schilling
17:15
17:15
Major postoperative complications increase tumor recurrence rate and diminish long-term survival following resection for pancreatic ductal adenocarcinoma  (P36 | ID 403)
Andreas Andreou, Pauline Aeschbacher, Anna Wenning, Daniel Candinas, Beat Gloor
17:20
17:20
Characterization of p53-status dependent EZH2 Activity in Pancreatic Cancer Progression and Treatment  (P37 | ID 418)
Lennart Versemann, Shilpa Patil, Zhe Zhang, Waltraut Kopp, Christin Kellner, Volker Ellenrieder, Elisabeth Hessmann
17:25
17:25
Longitudinal characterization of primary cells derived from PDAC Patient-Derived-Xenograft models  (P38 | ID 429)
Charlotte Sigg, Karly Conrads , Christin Kellner, Waltraut Kopp, Jennifer Appelhans, Mark-Sebastian Bösherz, Elisabeth Heßmann
17:30
17:30
Hdac2 facilitates pancreatic cancer metastasis  (P39 | ID 453)
Lukas Krauß, Bettina Urban, Sieglinde Hastreiter, Carolin Schneider, Patrick Wenzel, Zonera Hassan, Matthias Wirth, Katharina Lankes, Andrea Terasi, Christine Clement, Filippo Cernilogar, Rupert Öllinger, Niklas de Andrade Krätzig, Thomas Engleitner , Roland Schmid, Katja Steiger, Roland Rad, Oliver Krämer, Maximilian Reichert, Dieter Saur, Gunnar Schotta, Günter Schneider
16:55 - 17:50
16:55 - 17:50Poster Room
Poster Lounge 5
Chair: Rüdiger Braun
Poster Room
16:55
16:55
Spatially targeting pancreatic cancer to enhance local treatment efficacy and allow systemic immune response  (P41 | ID 554)
Kornelia Aigner, Yogesh Vashist, Karl Reinhard Aigner
17:00
17:00
The lymph node ratio correlates with parameters of aggressive biology and is a strong and independent prognostic factors ampullary cancer – a retrospective bicentric study  (P42 | ID 527)
Miljana Vladimirov, Lisa Blankenhorn, Kerstin Moskorz, Myriam Neininger, Thomas Papadopoulos, Hubert Stein, Ulrich Wellner, Tobias Keck, Dirk Bausch, Louisa Bolm, Meike ten Winkel, Steffen Deichmann, Kim Honselmann
17:05
17:05
Role of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic cancer   (P43 | ID 335)
Silje Beckinger, Leon Aldag, Sandra Krüger, Steffen Heckl, Christoph Röcken, Susanne Sebens
17:10
17:10
Phenotypic and molecular characterization of duct- and acinar-derived pancreatic ductal adenocarcinoma  (P44 | ID 341)
Jingxiong Hu, Yuanyuan Yu, Kathleen Schuck, Christoph Michalski, Andre Mihaljevic, Bo Kong
17:15
17:15
Deciphering the role of the EZH2 epigenetic factor in ATM-deficient pancreatic cancer progression  (P34 | ID 364)
Elodie Roger, Luise Goldfuß, Johann Gout, Lukas Perkhofer, Thomas Seufferlein, Alexander Kleger, Elisabeth Heßmann
17:20
17:20
Investigating dynamic crosstalks between cancer-associated fibroblasts and tumor cells in ATM-deficient pancreatic cancer  (P45 | ID 343)
Elodie Roger, Frank Arnold, Eleni Zimmer, Dharini Srinivasan, Lukas Perkhofer, Thomas Seufferlein, Johann Gout, Alexander Kleger
17:25
17:25
Neoadjuvant chemotherapy suppresses immune function and favours neuronal activity in patients with pancreatic ductal adenocarcinoma  (P46 | ID 384)
Maximilian Kießler, Carmen Mota-Reyes, Helmut Friess, Rouzanna Istvanffy, Ihsan Ekin Demir
17:30
17:30
Characterization of the mechanistic and functional implications of ARID1A deficiency in inflammation and tumor-promoting processes in PDAC  (P48 | ID 415)
Maria Ulisse
17:35
17:35
Intraabdominal hypertension as a risk factor of gastrointestinal fistula formation in patients with severe acute pancreatitis  (P50 | ID 467)
Olexii Dronov, Inna Kovalska, Andrii Horlach, Tetiana Ivanets, Ivanna Shchyhel, Fedir Prytkov
16:55 - 17:50
16:55 - 17:50Poster Room
Poster Lounge 6
Chair: Louisa Bolm
Poster Room
16:55
16:55
Experience in the use of pancreatogastroanastomosis at the reconstructive stage at a pancreatoduodenectomy.  (P51 | ID 426)
Bohdan Tsubera
17:00
17:00
Synergic crosstalk between intratumoral nerves and myeloid derived suppressor cells in pancreatic cancer via neuronal-derived expression of CXCL8   (P52 | ID 437)
Carmen Mota Reyes, Teresa Zwick, Kaan Cifcibasi, Alexander Muckenhuber, Wilko Weichert, Helmut Friess, Hana Algül, Ruzanna Istvanffy, Ihsan Ekin Demir
17:05
17:05
The porcine urinary bladder mimics a pancreatic niche and enables cancer modelling  (P53 | ID 440)
Michael Karl Melzer, Markus Breunig, Frank Arnold, Felix Wezel, Anca Azoitei, Elodie Roger, Jana Krüger, Jessica Merkle, Lena Schütte, Friedemann Zengerling, Ninel Azoitei, Thomas Seufferlein, Meike Hohwieler, Christian Bolenz, Cagatay Günes, Johann Gout, Alexander Kleger
17:10
17:10
Single cell analysis of primary isolated and cultured pancreatic cancer-associated fibroblasts  (P54 | ID 445)
Yoshiaki Sunami, Luca Tosti, Matthias Sommerer, Jörg Kleeff
17:15
17:15
Characterizing stromal subtypes in patient-derived Xenograft Models of Pancreatic Cancer  (P55 | ID 463)
Louisa Bolm, Natalie Petruch, Pascal Finetti, Andrew L. Warshaw, Carlos Férnandez-Del Castillo, Andrew S. Liss
17:20
17:20
Short and long-term outcomes of surgical treatment of resectable and borderline resectable pancreatic adenocarcinoma  (P56 | ID 492)
Yevhenii Trehub, Oleg Vasiliev
17:25
17:25
Transcriptomic landscape of human epithelial and stromal cells purified from cancer and normal tissue dissects cross-talks and deregulated signaling in PDAC   (P57 | ID 512)
Elisa Espinet, Zuguang Gu, Jing Yang, Nathalia A Giese, Vanessa Vogel, Thilo Hackert, Oliver Strobel, Matthias Schlesner, Wilko Weichert, Martin Sprick, Andreas Trumpp
17:30
17:30
Interleukin-13-receptor-alpha-1 plays a crucial role in pancreatic cancer progression   (P58 | ID 518)
Qi Kang, Jingwei Shi, Christoph Michalski, Marko Kornmann, Benno Traub
17:35
17:35
Increased frequencies of IL3 producing memory B cells in lymph node 8a of pancreatic ductal adenocarcinoma patients  (P59 | ID 522)
Paul David, Frederik Hansen, Anke Mittelstaedt, Anne Jacobsen, Malgorzata Podolska, Dina Kouhestani, Maxilillian Brunner, Christian Krautz, Robert Gruetzmann, Alan Benard, Georg Weber
17:40
17:40
The immunogenic phenotype triggered by acquired PARP-inhibitor resistance in ATM-deficient pancreatic cancer cells  (P60 | ID 525)
Frank Arnold, Elodie Roger, Thomas Seufferlein, Johann Gout, Alexander Kleger
17:00 - 17:40
17:00 - 17:40Meeting Room
International Session Pancreatology I
Chairs: Hryhoryi Lapshyn, Yogesh Vashist
Meeting Room
Minimal Invasive Pancreatic Surgery in Russia
Igor Khatkov
Multimodal Pancreatic Cancer Treatment in Ukraine
Sergyi Zemskov
Advanced Surgery for Pancreatic Cancer in Georgia
Ilya Gotsadze
Development of Pancreatic Surgery in Azerbaijan
Mubariz Aliev
17:50 - 19:15
17:50 - 19:15Lecture Hall
Session II: Pancreatitis and Pancreatic Cancer
Chairs: Lukas Perkhofer, Patrick Michl
Lecture Hall
Keynote: Does the pathophysiology of chronic pancreatitis justify a conservative approach?
Matthias Löhr
Keynote: Neoadjavant therapy in pancreatic cancer - why I do it.
Cristina Ferrone
Radiological prediction of resectability after neoadjuvant therapy - An analysis of pancreatic cancer patients treated with total neoadjuvant FOLFIRINOX and chemoradiotherapy  (ID 464)
Louisa Bolm, Birte Purschke, Theodoros P. Michelakos, Hiroki Sato, Natalie Petruch, Martina Nebbia, Motaz Qadan, Cristina Ferrone, Keith Lillemoe, Carlos Férnandez-Del Castillo
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant therapy  (ID 354)
Peter Bailey, Zhou Xu, Roma Kurilov, Jing-Yu An, Kai Hu, Teresa Peccerella, Stephanie Rossler, Katrin Pfutze, Angela Schulz, Stephan Wolf, Christoph Springfeld, Markus Buchler, Frank Bergmann, John Neoptolemos, Benedikt Brors, Thilo Hackert, Franco Fortunato
Impact of targeted SHP2-inhibition +/- MAPK-Inhibition on metabolic rewiring in pancreatic cancer  (ID 346)
Philipp Hafner, Dietrich A. Ruess, Huda Jumaa, Friederike Nollman, Luciana Hannibal
19:15 - 19:25
19:15 - 19:25Lecture Hall
Study Presentation: A Multicenter Randomized Trial.
Chairs: Steffen Deichmann, Patrick Michl
Lecture Hall
Clinical Impact of Stump Closure Reinforced With Hemopatch on the Prevention of Clinically Relevant Pancreatic Fistula After Distal Pancreatectomy: A Multicenter Randomized Trial
Abraham Fingerhut and Selman Uranüs
19:00 - 20:00
19:00 - 20:00General Assembly
General Assembly
General Assembly
20:00 - 21:00
20:00 - 21:00Meeting Room
Discover Luebeck: Live City Tour
Let us surprise you and discover Lübeck from all over the world.
Meeting Room
21:00 - 22:00
21:00 - 22:00Lounge
Networking
Lounge
08:30 - 09:55
08:30 - 09:55Lecture Hall
Session III: Pancreatic Surgery
Chairs: Dirk Bausch, Ilaria Pergolini
Lecture Hall
Keynote: Robotic Pancreatic Surgery - The Cutting Edge of Visceral Surgery
Ugo Boggi
Keynote: Pancreatic Surgery after Neoadjuvant Therapy - The New Challenge
Tobias Keck
Pancreatoduodenectomy with or without prophylactic falciform ligament wrap around the hepatic artery for prevention of postpancreatectomy haemorrhage: a randomized clinical trial (PANDA trial)  (ID 423)
Thilo Welsch, Benjamin Müssle, Marius Distler, Robert Grützmann, Jörg Kleeff, Helmut Friess, Waldemar Uhl, Jürgen Weitz
Visceral Debranching followed by neoadjuvant chemotherapy and pancreatic resection for locally advanced pancreatic cancer: Case report and PREVADER study presentation   (ID 281)
Artur Rebelo, Jörg Ukkat, Ulrich Ronellenfitsch, Christoph W. Michalski, Patrick Michl, Sebastian Krug, Jörg Kleeff
Defining an optimal time span between neoadjuvant chemotherapy and pancreatic surgery for malignancy: cut or wait?  (ID 481)
Florian Oehme, Felix von Bechtolsheim, Sebastian Hempel, Christian Teske, Olga Radulova-Mauersberger, Marius Distler, Jürgen Weitz, Christoph Kahlert
09:55 - 10:15
09:55 - 10:15Exhibition Hall
Industrial Exhibition and Coffee
Exhibition Hall
10:15 - 12:00
10:15 - 12:00Lecture Hall
Session IV: Clinical Trials and Novel Therapies
Chairs: Jens Höppner, Bernhard Renz
Lecture Hall
Keynote: Curative Intent Treatment of Metastatic Pancreatic Cancer ?
Julia Mayerle
Keynote: Where is the Way to Personalized Oncology in Pancreatic Cancer ?
John Neoptolemos
Keynote: Minimally invasive pancreatic surgery - can it improve our outcomes ? Lessons from Dutch and European Trials.
Marc Besselink
Influence of extracorporeal cytokine adsorption on hemodynamic stability in severe acute pancreatitis – results of the PACIFIC trial  (ID 330)
Sebastian Rasch, Sengül Sancak, Johanna Erber, Johannes Roman Wießner, Dominik Schulz, Christina Huberle, Hana Algül, Roland M. Schmid, Tobias Lahmer
Translational development of a polysaccharide microsphere-based intraoperative predictive indicator of postoperative pancreatic fistula  (ID 501)
Thomas M. Pausch, Clara Mitzscherling, Ophelia Aubert, Marc Bartel, Thomas Bruckner, Felix Kommoss, Thilo Hackert
Epigenetic Drug Screening Defines a PRMT5 Inhibitor Sensitive Pancreatic Cancer Subtype  (ID 413)
Katharina Lankes*, Felix Orben*, Christian Schneeweis, Zonera Hassan, Hannah Jakubowsky, Lukas Krauß, Fabio Boniolo, Carolin Schneider, Arlett Schäfer, Christoph Schlag, Bo Kong, Rupert Öllinger, Roland Rad, Christian J. Braun, Matthias Wirth, Maximilian Reichert, Dieter Saur, Günter Schneider
12:00 - 12:15
12:00 - 12:15Lecture Hall
Flash-Talks of selected posters (P61 - P121)
Chairs: Jens Höppner, Bernhard Renz
Lecture Hall
Flash Talk: The impact of sarcopenia on the risk of postoperative pancreatic fistula after pancreatoduodenectomy  (ID 279 | P76)
Teresa Perra, Alberto Porcu
Flash Talk: Drug resistance of different pancreatic cancer stem cell populations can be overcome by sequential chemotherapy  (ID 308 | P92)
Lisa-Marie Philipp, Susanne Sebens
Flash Talk: Metavert, a dual inhibitor of GSK3B and HDACs, in combination with cytotoxic drugs is synergistic in human pancreatic cancer cells and organoids  (ID 325 | P93)
Jingyu An, Hu Kai, Xu Zhou, Teresa Peccerella, Hackert Thilo, Georg Beyer, Julia Mayerle, Mouad Edderkaoui, Stephen Pandol, Springfeld Christoph, Peter Bailey, Franco Fortunato, John Neoptolemos
Flash Talk: Proteome profiling of PDAC and specific detection of kallikrein proteases -6 and -10 by targeted and shotgun mass spectrometry  (ID 332 | P103)
Janina Werner, Patrick Bernhard, Klemens Fröhlich, Matthias Fahrner, Johannes Eberhard, Felix Rückert, Peter Bronsert, Oliver Schilling
Flash Talk: How to predict microlithiasis in idiopathic pancreatitis - a machine learning derived tool  (ID 348 | P65)
Micha? ?orniak, Simon Sirtl, Eric Hohmann, Julia Mayerle, Ujjwal Mahajan
Flash Talk: Drain use in pancreatic surgery: results from an international survey among experts of the International Study Group for Pancreatic Surgery (ISGPS)  (ID 370 | P78)
Ilaria Pergolini, Stephan Schorn, Rüdiger Göß, Alexander Novotny, Güralp O. Ceyhan, Helmut Friess, Ihsan E. Demir
Flash Talk: Neuron-triggered CCL2/CCR4/p-Paxillin pathway as a novel mechanism of neural invasion in pancreatic adenocarcinoma.  (ID 386 | P104)
Ruzanna Istvanffy, Xiaobo Wang, Linhan Ye, Lei Ren, Kalliope N. Diacopoulos, Melanie Lashinger, Hanna Alguel, Helmut Friess, Gueralp O. Cheyhan, Marina Lesina, Ekin I. Demir, Baiba Vilne
Flash Talk: Comparative analysis of DNA mutations in PDAC tumors and corresponding cf-/evDNA liquid biopsy samples upon panel sequencing   (ID 432 | P72)
Mareike Waldenmaier, Mareen Morawe, Tim Eiseler, Thomas Seufferlein
Flash Talk: Colocalization of pancreas eQTLs with risk loci from alcoholic and novel non-alcoholic chronic pancreatitis GWAS reveals disease causing mechanisms  (ID 503 | P70)
Andreas W. Schmidt, Andreas Kühnapfel, Holger Kirsten, Heiko Witt, Helmut Laumen, Jonas Rosendahl
Flash Talk: Liquid Biopsy For Monitoring Pancreatic Cancer Recurrence  (ID 533 | P74)
Teresa Colbatzky, Ulrike Heger, Fawaz Al-Shaheri, Lucas Sperling, Christin Tjaden, Ulf Hinz, Nathalia Giese, Thilo Hackert, Jörg Hoheisel
12:15 - 13:10
12:15 - 13:10Poster Room
Poster Lounge 7
Chair: Matthias Ilmer
Poster Room
12:15
12:15
Pancreatic resection with perioperative drug repurposing of propranolol and etodolac: the phase-II randomised placebo controlled PROSPER trial  (P61 | ID 499)
Felix J. Hüttner, Ilse Rooman, Gauthier Bouche, Oliver Strobel, Phillip Knebel, André L. Mihaljevic, Thilo Hackert, Markus W. Büchler, Markus K. Diener
12:20
12:20
DIAGNOSTICS OF THE POST-TRAUMATIC PANCREATITIS  (P62 | ID 514)
Olena Babkina, Svitlana Danylchenko
12:25
12:25
Chronic liver disease increases mortality following pancreatoduodenectomy  (P63 | ID 296)
Jana Enderes, Jessica Teschke, Steffen Manekeller, Tim O. Vilz, Jörg C. Kalff, Tim R. Glowka
12:30
12:30
Impact of Sample Storage on the Serum Proteome Quality  (P64 | ID 441)
Thorben Sauer
12:35
12:35
How to predict microlithiasis in idiopathic pancreatitis - a machine learning derived tool  (P65 | ID 348)
Micha? ?orniak, Simon Sirtl, Eric Hohmann, Julia Mayerle, Ujjwal Mahajan
12:40
12:40
SBPC Chronic Pancreatitis Registry: results of an database structure implementation at the University Medical Center Schleswig Holstein, Campus Lübeck  (P66 | ID 433)
Natalie Frenzel, Meike ten Winkel, Rüdiger Braun, Louisa Bolm, Steffen Deichmann, Kim Honselmann, Hryhoriy Lapshyn, Tobias Keck, Ulrich Wellner
12:45
12:45
The embryonic transcription factor Tbx3 fine-tunes regeneration from acute pancreatitis   (P67 | ID 439)
Michael Karl Melzer, Frank Arnold, Johann Gout, Silvia Schirge, Cagatay Günes, Christian Bolenz, Thomas Seufferlein, Lukas Perkhofer, Alexander Kleger
12:50
12:50
Results of treatment fluid collections in acute pancreatitis using minimally invasive procedures  (P68 | ID 477)
Igor A. Kryvoruchko
12:55
12:55
Retrospective study of routine laboratory indices in patients with necrotizing pancreatitis in the prospect of their use for the timing of operative pancreatic debridement  (P69 | ID 485)
Yaroslav Susak, Oksana Lobanova, Mykhailo Maksymenko, Larysa Skivka, Olexandr Tkachenko, Illia Tiuliukin
13:00
13:00
Colocalization of pancreas eQTLs with risk loci from alcoholic and novel non-alcoholic chronic pancreatitis GWAS reveals disease causing mechanisms  (P70 | ID 503)
Andreas W. Schmidt, Andreas Kühnapfel, Holger Kirsten, Heiko Witt, Helmut Laumen, Jonas Rosendahl
12:15 - 13:10
12:15 - 13:10Poster Room
Poster Lounge 8
Chair: Matthias Reeh
Poster Room
12:20
12:20
Comparative analysis of DNA mutations in PDAC tumors and corresponding cf-/evDNA liquid biopsy samples upon panel sequencing   (P72 | ID 432)
Mareike Waldenmaier, Mareen Morawe, Tim Eiseler, Thomas Seufferlein
12:25
12:25
Hamburg Glasgow Classification for Pancreatic Cancer  (P73 | ID 498)
Thaer S. A. Abdalla, Matthias Reeh, Jakob R. Izbicki
12:30
12:30
Stratifying treatment in pancreatic cancer patients via cell-free tumor DNA (tcfDNA)  (P75 | ID 534)
Azadeh Azizian, Alexander König, Michael Ghadimi, Jochen Geadcke
12:35
12:35
The impact of sarcopenia on the risk of postoperative pancreatic fistula after pancreatoduodenectomy  (P76 | ID 279)
Teresa Perra, Alberto Porcu
12:40
12:40
Pancreatorrhaghia in patients with complicated chronic pancreatitis  (P77 | ID 283)
Ihor Pavlyk, Oleh Kanikovsky, Oleksandr Makhovskyi, Yuliia Punko
12:45
12:45
Drain use in pancreatic surgery: results from an international survey among experts of the International Study Group for Pancreatic Surgery (ISGPS)  (P78 | ID 370)
Ilaria Pergolini, Stephan Schorn, Rüdiger Göß, Alexander Novotny, Güralp O. Ceyhan, Helmut Friess, Ihsan E. Demir
12:50
12:50
Case report: Malignant mucinous cystic neoplasm of pancreas  (P79 | ID 412)
Veronika Rozhkova
12:55
12:55
Length of small bowel resection is not associated with postoperative immediate New Onset of Diabetes mellitus after pancreaticoduodenectomy  (P80 | ID 446)
Tengis Tschaidse, Florian Kühn, Viktor von Ehrlich-Treuenstätt, Felix Hofmann, Jens Werner, Bernhard Renz, Matthias Ilmer
13:00
13:00
Endoscopic ultrasonography(EUS)-guided drainage of the pancreatic duct (EU-PD) to treat symptomatic retention pancreatitis - a minimally invasive alternative of surgical re-intervention in patients with altered anatomy of the upper GI tract  (P71 | ID 548)
T. Buechner
12:15 - 13:10
12:15 - 13:10Poster Room
Poster Lounge 9
Chair: Georg Weber
Poster Room
12:15
12:15
Irf3 and Irf7 are important mediators of tumor cell aggressiveness in pancreatic cancer  (P82 | ID 459)
Lisa Fahr, Simone Benitz, Tobias Straub, Jurik Mutter, Hannah Lisiecki, Ujjwal M. Mahajan, Georg Beyer, Katja Steiger, Jörg Kleeff, Christoph W. Michalski, Julia Mayerle, Ivonne Regel
12:20
12:20
Classical and basal-like pancreatic cancer lines respond differently towards epigenetic drug treatment   (P83 | ID 460)
Quan Zhou, Svenja Pichlmeier, Tobias Straub, Anna Kirmayr, Simone Benitz, Ujjwal Mahajan, Lisa Fahr, Christoph W Michalski, Jörg Kleeff, Julia Mayerle, Ivonne Regel
12:25
12:25
Prognostic markers for the response of nanoliposolal Irinotecan in subsequent line treament of advanced pancreatic cancer - a retrospective analysis  (P84 | ID 489)
Marius Brunner, Lena Marie Heinrich, Alexander König, Volker Ellenrieder
12:30
12:30
Multiplex IHC  (P85 | ID 508)
Theresa Weltermann, Ahmed Alnatsha, Ivonne Regel, Christian Schulz, Julia Mayerle, Ujjwal Mukund Mahajan
12:35
12:35
FAPI- PET CT for detecting recurrence of pancreatic cancer   (P86 | ID 529)
Lucas Sperling, Teresa Colbatzky, Manuel Röhrich, Christin Tjaden, Nathalia Giese, Ulf Hinz, Uwe Haberkorn, Thilo Hackert, Ulrike Heger
12:40
12:40
Precision vascular anatomy for the minimally invasive pancreatic resections  (P87 | ID 282)
Stanislav Litkevych, Joachim Wellner, Ulrich F. Wellner, Tobias Keck
12:45
12:45
Risk Factors for Mortality in Patients Undergoing Major Pancreatic Surgery and Influence of Surgical Expertise: Data from the German StuDoQ-/Pancreas Registry  (P89 | ID 516)
Andreas Minh Luu, Philipp Höhn, Tim Fahlbusch, Waldemar Uhl, Orlin Belyaev
12:50
12:50
Complication Management after Pancreatic Resection - Retrospective Analysis of Different Therapeutical Regimen for Severe Complications in a Large Volume Center  (P90 | ID 538)
Tabea Boeckmann, Steffen Deichmann, Louisa Bolm, Rüdiger Braun, Hryhoriy Lapshyn, Ekaterina Petrova, Dirk Bausch, Tobias Keck, Ulrich Wellner, Kim Christin Honselmann
12:55
12:55
Robotic segmental pancreatic resection for a central neuroendocrine tumor of the pancreas  (P88 | ID 455)
Georg Weber, Robert Grützmann, Christian Krautz
13:05
13:05
Body mass index (BMI) in pancreatic ductal adenocarcinoma (PDAC) is a critical factor for an altered bile duct microbiology after pancreaticoduodenectomy  (P81 | ID 536)
Viktor von Ehrlich-Treuenstätt, Jan D'Haese, Maximilian Weniger, Markus Guba, Joachim Andrassy, Martin Angele, Jens Werner, Bernhard Renz, Matthias Ilmer
12:15 - 13:10
12:15 - 13:10Poster Room
Poster Lounge 10
Chair: Felix Rückert
Poster Room
12:15
12:15
Orointestinal microbiome as predictor of pancreatic mass dignity and post pancreatectomy complications  (P91 | ID 285)
Christoph Ammer-Herrmenau, Catharina Lingens, Nina Pfisterer, Albrecht Neesse
12:20
12:20
Drug resistance of different pancreatic cancer stem cell populations can be overcome by sequential chemotherapy  (P92 | ID 308)
Lisa-Marie Philipp, Susanne Sebens
12:25
12:25
Metavert, a dual inhibitor of GSK3B and HDACs, in combination with cytotoxic drugs is synergistic in human pancreatic cancer cells and organoids  (P93 | ID 325)
Jingyu An, Hu Kai, Xu Zhou, Teresa Peccerella, Hackert Thilo, Georg Beyer, Julia Mayerle, Mouad Edderkaoui, Stephen Pandol, Springfeld Christoph, Peter Bailey, Franco Fortunato, John Neoptolemos
12:30
12:30
Neoadjuvant chemotherapy induces GATA6-upregulation relating to molecular subtype switching and chemoresistance in pancreatic cancer  (P94 | ID 328)
Kai Hu, Shigenori Ei, Roma Kurilov, Xu Zhou, Jingyu An, Teresa Peccerella, Peter Bailey, Christoph Springfeld, Frank Bergmann, Benedikt Brors, Franco Fortunato, Markus W Büchler, John Neoptolemos, Thilo Hackert
12:35
12:35
Pleiotropic role of TRAIL-R4 in pancreatic cancer cells.  (P95 | ID 339)
Sina Schubert, Doaa Tawfik, Anna Trauzold, Monika Szczepanowski, Wolfram Klapper
12:40
12:40
Patient-derived Organoid based automated high-throughput pharmacotyping for treatment selection of pancreatic ductal adenocarcinoma  (P96 | ID 340)
Lena Schütte, Jessica Merkle, Alica Beutel, Yazid Resheq, Johann Gout, Thomas Seufferlein, Alexander Kleger
12:45
12:45
Risk factors for pancreatic cancer in patients with new onset diabetes - systematic review and meta-analysis  (P97 | ID 405)
Claudia Mellenthin, Vasile Balaban, Ana Dugic, Stephane Cullati, Bernhard Egger
12:50
12:50
ALDH1A3 mediates an AP-1-dependent enhancer network promoting pancreatic malignancy  (P98 | ID 406)
Shuang Nie, Kathleen Schuck, Andre Mihaljevic, Christoph Michalski, Bo Kong
12:55
12:55
Implications of preoperative symptoms on patient survival after pancreatoduodenectomy for pancreatic ductal adenocarcinoma - a DGAV StuDoQ|Pancreas registry study  (P99 | ID 451)
Yannic Elser, Tabea Böckmann, Louisa Bolm, Meike Ten Winkel, Steffen Deichmann, Rüdiger Braun, Tobias Keck, Ulrich Wellner, Kim Christin Honselmann, Hryhoriy Lapshyn
13:00
13:00
Pharmacological and genetic disruption of the JNK pathways cause opposing effects on pancreatic cancer cells  (P100 | ID 456)
Jingwei Shi, Qi Kang, Xing Yang, Christoph Michalski, Marko Kornmann, Benno Traub
12:15 - 13:10
12:15 - 13:10Poster Room
Poster Lounge 11
Chair: Bo Kong
Poster Room
12:15
12:15
Neuronal glutamate promotes pancreatic cancer cell migration through neuro-cancer synapses that fuel the GRIN2D-EZH2-E2F1-RB pathway  (P102 | ID 291)
Lei Ren, Güralp O Ceyhan, Helmut Friess, Rouzanna Istvanffy, Ihsan Ekin Demir
12:20
12:20
Proteome profiling of PDAC and specific detection of kallikrein proteases -6 and -10 by targeted and shotgun mass spectrometry  (P103 | ID 332)
Janina Werner, Patrick Bernhard, Klemens Fröhlich, Matthias Fahrner, Johannes Eberhard, Felix Rückert, Peter Bronsert, Oliver Schilling
12:25
12:25
Neuron-triggered CCL2/CCR4/p-Paxillin pathway as a novel mechanism of neural invasion in pancreatic adenocarcinoma.  (P104 | ID 386)
Ruzanna Istvanffy, Xiaobo Wang, Linhan Ye, Lei Ren, Kalliope N. Diacopoulos, Melanie Lashinger, Hanna Alguel, Helmut Friess, Gueralp O. Cheyhan, Marina Lesina, Ekin I. Demir, Baiba Vilne
12:30
12:30
Analysis of immune checkpoint regulator PD-L1 on tumor and stroma cells in pancreatic cancer  (P105 | ID 401)
Tina Daunke, Sascha Rahn, Sandra Krüger, Daniela Wesch, Christoph Röcken, Susanne Sebens
12:35
12:35
Pancreatic proteases mediate pain in pancreatic cancer  (P106 | ID 404)
Phillip Gärtner, Okan Safak, David Jungwirth, Sergey Tokalov, Helmut Friess, Rouzanna Istvanffy, Ihsan Ekin Demir
12:40
12:40
TNF? induces classical-to-basal-like subtype switch and promotes tumor progression in pancreatic cancer  (P107 | ID 420)
Mengyu Tu, Lukas Klein, Elisa Espinet, Theodoros Georgomanolis, Friederike Penz, Laura Urbach, Florian Wegwitz, Xiaojuan Li, Kamil Bojarczuk, Philipp Ströbel, Andreas Trumpp, Argyris Papantonis, Volker Ellenrieder, Shiv Singh
12:45
12:45
Organotypic slice cultures of pancreatic ductal adenocarcinoma as preclinical model for development of personalized treatment strategies  (P108 | ID 424)
Benjamin Heckelmann, Olha Lapshyna, Susanne Eckelmann, Louisa Bolm, Kim Honselmann, Oliver Schilling, Maren Stillger, Tobias Keck, Peter Bronsert , Matthias Brandenburger, Ulrich Wellner, Rüdiger Braun
12:50
12:50
Axon Guidance Receptor ROBO3 Modulates Subtype Identity and Prognosis via AXL-associated Inflammatory Network in Pancreatic Cancer  (P109 | ID 436)
Niklas Krebs, Lukas Klein, Florian Wegwitz, Elisa Espinet, Carlo Maurer, Mengyu Tu, Xingbo Xu, Stefan Küffer, Andreas Trumpp, Phillip Ströbel, Rolf Brekken, Volker Ellenrieder, Shiv K. Singh
12:55
12:55
Human Organoid co-culture as a model to study pancreatic fibroblast subtypes  (P110 | ID 458)
Xing Yang, Jingwei Shi, Qi Kang, Maximilian Denzinger, Christoph Michalski, Marko Kornmann, Benno Traub
12:15 - 13:10
12:15 - 13:10Poster Room
Poster Lounge 12
Chair: Georg Beyer
Poster Room
12:15
12:15
Influence of microbial colonization and pancreatic pathology on outcome after pancreatic head resection  (P111 | ID 600)
Max Grabowski
12:20
12:20
Allelic regulation of CK19 during maturation of pancreatic ductal cells  (P112 | ID 345)
Jana Krüger, Markus Breunig, Meike Hohwieler, Alexander Kleger
12:25
12:25
Improving pancreatic lineage commitment of human pluripotent stem cells  (P113 | ID 443)
Sarah Merz, Markus Breunig, Meike Hohwieler, Alexander Kleger
12:30
12:30
Employing endogenous human peptides to disrupt tumor-stroma crosstalk and eliminate migrating CSCs by targeting CXCR4 receptor in PDAC  (P114 | ID 465)
Kanishka Tiwary, Anton Lahusen, Mirja Harms, Bastian Beitzinger, Roman Schmid, Syeda Inaas, Stefanie Hauff, Karolin Walter, Alexander Kleger, Mika Lindén, Thomas Seufferlein, Jan Münch, Patrick C. Hermann
12:35
12:35
Compartment specific role of Dkk3 in the carcinogenesis of Pancreatic ductal adenocarcinoma (PDAC)  (P115 | ID 487)
Dharini Srinivasan, Frank Arnold, Johann Gout, Elodie Roger, Alexander Kleger
12:40
12:40
Experience of total pancreatectomies in a specialized center  (P117 | ID 419)
Mariia Onyshchenko, Olexiy Dronov, Sergey Zemskov, Petro Bakunets, Yuriy Bakunets
12:45
12:45
The impact of preoperative biliary drainage on postoperative survival in patients with malignant obstructive jaundice  (P118 | ID 450)
Olexii Dronov, Inna Kovalska, Petro Bakunets, Yurii Bakunets, Lyudmila Levchenko, Fedir Prytkov
12:50
12:50
Outcome of extended resection after neoadjuvant therapy in pancreatic carcinoma  (P119 | ID 483)
Denise Charlotte Schütte, Ulrike Heger, Ulla Klaiber, Ulf Hinz, Markus W. Büchler, Thilo Hackert
12:55
12:55
Preoperative bile duct stenting reduces survival in resectable pancreatic cancer  (P120 | ID 504)
Maximilian Weniger, Meline Böhm, Matthias Ilmer, Jens Werner, Jan D'Haese
12:25 - 13:05
12:25 - 13:05Meeting Room
International Session Pancreatology II
Chairs: Hryhoryi Lapshyn, Sergyi Zemskov
Meeting Room
12:25
12:25
Radiation Therapy in Pancreatic Cancer in Ukraine
Oksana Zemskova
12:35
12:35
New Conception for LA-PDAC: Arterial Resection and Reconstruction first
Vyacheslav Ivanovich Egorov
12:45
12:45
Surgery for Chronic Pancreatitis in Georgia
Georgi Gerliani
12:55
12:55
Management of Acute Pancreatitis in Ukraine
Tetiana Formanchuk
13:10 - 13:15
13:10 - 13:15Exhibition Hall
Break
Please visit the Industrial Exhibition
Exhibition Hall
13:15 - 14:00
13:15 - 14:00Lecture Hall
Nordmark Symposium: Pancreas & Microbiome
Chair: Markus M. Lerch
Lecture Hall
13:15
13:15
Pancreas & Microbiome: Physiological and pathological interactions between the exocrine pancreas and intestinal microbiota
Fabian Frost
13:15 - 14:00
13:15 - 14:00Meeting Room
AG Pankreas Meeting
Meeting Room
14:00 - 14:05
14:00 - 14:05Exhibition Hall
Break
Please visit the Industrial Exhibition
Exhibition Hall
14:05 - 15:15
14:05 - 15:15Lecture Hall
Session V: Endoscopy
Chairs: Albrecht Neeße, Martha Kirstein
Lecture Hall
14:05
14:05
Keynote: Advanced Endoscopic Management of Pancreatitis
Alexander Arlt
14:25
14:25
Keynote: Endoscopy (or Radiology) in Diagnosis and Follow-up of Cystic Neoplasms of the Pancreas ?
Albrecht Neeße
14:45
14:45
Endoscopic papillectomy compared to surgery for ampullary lesions: a propensity-score matching analysis   (ID 542)
Marcus Hollenbach, Christian Heise, Einas Abou Ali, Aiste gulla, Francesco Auriemma, Sara Regner, Sebastian Gaujoux
15:00
15:00
Consensus Definition of Microlithiasis and Sludge as Cause of Biliary Pancreatitis: Results from a systematic review of the literature, expert survey and consensus meeting  (ID 271)
Simon Sirtl, Michal ?orniak, Georg Beyer, Jörg Schirra, Christian Schulz , Ujwal M. Mahajan, Markus M. Lerch, Julia Mayerle, The LMU Mi in the app
14:00 - 15:30
14:00 - 15:30Meeting Room
ESPAC6-Meeting
Meeting Room
15:30 - 15:45
15:30 - 15:45Exhibition Hall
Industrial Exhibition and Coffee
Exhibition Hall
15:45 - 17:25
15:45 - 17:25Lecture Hall
Session VI: Pancreatic Cancer
Chairs: Christoph Michalski, Susanne Sebens
Lecture Hall
15:45
15:45
Keynote: The Matrisome in pancreatic cancer
Andrew Liss
16:05
16:05
Oxford Discussion | Branch duct type IMPN - observe or resect
Oliver Strobel and Giovanni Marchegiani
16:25
16:25
Combined exosomal CD40 and CD25 as potential liquid biopsy markers for the detection of pancreatitis and pancreatic cancer  (ID 502)
Dina Kouhestani, Anke Mittelstädt, Paul David, Izabela Swierzy, Lotta Roßdeutsch, Bettina Klösch, Maximilian Brunner, Anne Jacobsen, Alan Benard, Robert Grützmann, Christian Krautz, Georg Weber
16:40
16:40
Autonomous roles of ATM and P53 during pancreatic cancer carcinogenesis  (ID 342)
Johann Gout, Thomas Seufferlein, Alexander Kleger, Frank Arnold, Elodie Roger, Dharini Srinivasan, Lukas Perkhofer, Eleni Zimmer, Lena Schütte, Anna Härle
16:55
16:55
Raloxifene enhances the in vitro and in vivo efficacy of paclitaxel in pancreatic ductal adenocarcinoma   (ID 497)
Ioannis Pozios, Nina Hering, Emily Guenzler, Marco Arndt, Miriam Zibell, Martin Kreis, Hendrik Seeliger, Katharina Beyer, Carsten Kamphues
17:10
17:10
Elucidation of misp53-driven Subtype Specification and Function in Pancreatic Cancer  (ID 305)
Laura Urbach, Lukas Klein, Frederike Penz, Karly Conrads, Jens Löber, Shiv K. Singh, Volker Ellenrieder
17:25 - 17:45
17:25 - 17:45Exhibition Hall
Industrial Exhibition and Coffee
Exhibition Hall
17:45 - 19:10
17:45 - 19:10Lecture Hall
Session VII: Pancreatitis
Chairs: Julia Mayerle, Robert Jaster
Lecture Hall
17:45
17:45
Keynote: Walled of pancreatic necrosis and other nasty aspects after pancreatitis
Nicolas Zyromski
18:05
18:05
Keynote: Hereditary Pancreatitis - A perspective
Markus Lerch
18:25
18:25
Keynote: Postoperative Pancreatitis : A new Paradigm to Overcome Surgical Complications ?
Johanna Laukkarinen
18:40
18:40
The pancreatic proteases as new analgesic targets in acute and chronic pancreatitis  (ID 400)
Okan Safak, David Jungwirth, Phillip Gärtner, Sergey Tokalov, Helmut Friess, Ihsan Ekin Demir
18:55
18:55
Reduced skeletal muscle mass, but not sarcopenia, is common in patients with chronic pancreatitis  (ID 301)
Mats L. Wiese, Ali A. Aghdassi, Simone Gärtner, Trung Tran, Julia Doller, Fabian Frost, Ulrich Weiß, Fatuma Meyer, Luzia Valentini, Leif-A. Garbe, Cornelia Metges, Karen Bannert, Robert Jaster, Georg Lamprecht, Markus M. Lerch
19:10 - 19:20
19:10 - 19:20Exhibition Hall
Break
Please visit the Industrial Exhibition
Exhibition Hall
19:20 - 21:20
19:20 - 21:20Meeting Room
Award Ceremony and Get-together
Meeting Room
09:00 - 09:55
09:00 - 09:55Lecture Hall
Session VIII: NETs
Chairs: Florian Gebauer, Birte Kulemann
Lecture Hall
09:00
09:00
Keynote: Molecular Biology of pNEN
Sebastian Krug
09:20
09:20
Keynote: Molecular Imaging and Therapy in pNEN
Richard Baum
09:40
09:40
Peptide Mass Spectrometry Imaging (MSI) of Pancreatic Cancers and the Application of Open Source Analysis Tools for the Establishment of a Powerful and User-friendly Analysis Pipeline  (ID 380)
Maren Stillger, Melanie Foell, Martin Dieterle, Pia Hoenscheid, Martin Werner, Peter Bronsert, Oliver Schilling
09:55 - 10:15
09:55 - 10:15Exhibition Hall
Industrial Exhibition and Coffee
Exhibition Hall
10:15 - 12:25
10:15 - 12:25Lecture Hall
Session IX: Tumor Microenvironment, Stem Cells, Epigenetics
Chairs: Louisa Bolm, Ihsan Ekin Demir
Lecture Hall
10:15
10:15
Keynote: EMT in Pancreatic Cancer
Marc Stemmler
10:35
10:35
Keynote: Epigenetics in Pancreatic Cancer
Elisabeth Hessmann
10:55
10:55
BRD4-mediated cJUN/AP1 Enhancer Reprogramming Determines Basal-like Subtype Identity through Inflammatory Immune Intrusion in Pancreatic Cancer  (ID 333)
Lukas Klein, Mengyu Tu, Elisa Espinet, Frederike Penz, Laura Urbach, Athanasia Mizi, Stephan Hahn, Andreas Trumpp, Volker Ellenrieder, Argyris Papantonis, Shiv K. Singh
11:10
11:10
Label-free high-throughput digital holographic microscopy to characterize pancreatic cancer heterogeneity on a single-cell level   (ID 390)
Katja Peschke, Manuel Lengl, Stefan Röhrl, Carlo Maurer, Christian Klenk, David Fresacher, Farid Harb, Nawal Havez, Felix Orben, Rupert Öllinger, Dieter Saur, Roland Rad, Günter Schneider, Oliver Hayden, Klaus Diepold, Maximilian Reichert, Joanna Madej
11:25
11:25
mTORC1 is a crucial target to reprogram inflammatory desmoplastic stroma in pancreatic ductal adenocarcinoma  (ID 410)
Yuanyuan Yu, Kathleen Schuck, Andre Mihaljevic, Christoph Michalski, Bo Kong
11:40
11:40
Uncoupling protein 2 deficiency of non-cancerous tissues inhibits the progression of pancreatic cancer in mice  (ID 274)
Robert Jaster, Denis Revskij, Luise Ehlers, Sarah Rohde, Camilla Umstätter, Jakob Runst
11:55
11:55
Characterizing early oncogenic KRAS signaling in the context of pancreatic cancer using single-cell RNA sequencing   (ID 438)
Chantal Allgöwer, Sandra Wiedenmann, Matthias Meier, Meike Hohwieler, Alexander Kleger
12:10
12:10
Spatially resolved multiomics single-cell analyses inform mechanisms of immune-dysfunction in pancreatic cancer  (ID 526)
Suhail Yousuf, Mengjie Qiu, Lena V V Voithenberg, Johannes Hulkkonen, Dominic Hartmann, Margarete Mijatovic, Charles Imbusch, Axel Schulz, Henrik Mei, Bernhard Brune, Simon Anders, Benedict Brors, Mathias Heikenwälder, Matthias Gaida, Markus W Büchler, Andreas Weigert, Thilo Hackert, Susanne Roth
12:25 - 12:45
12:25 - 12:45Exhibition Hall
Industrial Exhibition and Coffee
Exhibition Hall
12:45 - 13:15
12:45 - 13:15Lecture Hall
SOBI Symposium: Unclear gastroenterological complaints? Chylomicronemia syndrome!
Lecture Hall
12:45
12:45
Significance and relevance of chylomicronemia syndrome
Michele Sorleto (Talk will be held in German).
13:00
13:00
Rare Cause of Hypertriglyceridemia: Familial Chylomicronemia Syndrome
Claudia Brückner (Talk will be held in German).
13:15 - 14:50
13:15 - 14:50Lecture Hall
Session X: Cystic Lesions
Chairs: Marius Distler, Miljana Vladimirov
Lecture Hall
13:15
13:15
Keynote: Innovative Diagnostics in Cystic Neoplasms of the Pancreas
Hanno Matthaei
13:35
13:35
Keynote: IPMN and Diabetes
Ilaria Pergolini
13:55
13:55
GerPaCyst- A German Pancreas Club Cyst registry: a protocol for a prospective, multicenter, interdisciplinary registry study  (ID 336)
Jonathan Marschner, Ulrich Wellner, Julia Bertram, Steffen Deichmann, Marko Damm, Sebastian Krug, Christoph Michalski, Tobias Keck, Kim Honselmann
14:10
14:10
IPMNs are diagnosed with limited accuracy despite modern imaging techniques and following the recommendations of current guidelines.  (ID 495)
Visvakanth Sivanathan, Priyanka Wacker, Markus Möhler
14:25
14:25
Round Table Discussion | The Way to Big Data in IPMN
Giovanni Marchegiani, Georg Beyer and Louisa Bolm
14:50 - 15:00
14:50 - 15:00Lecture Hall
Farewell and Invitation DPC 2023
Chairs: Robert Jaster, Ulrich Wellner
Lecture Hall
P1
P1
Pancreatitis – Microbiome As Predictor of Severity (P-MAPS): A prospective international multicentre translational study
Christoph Ammer-Herrmenau, Thomas Asendorf, Soeren Buchholz, Silke Cameron, Fabian Frost, Antonio Gomes, Robert Henker, Albrecht Hoffmeister, ?ukasz Nawacki, Arpád Panyko, Veit Phillip, Sebastian Rasch, Simon Sirtl, Mark Weingarten, Julia Woitalla, Volker Ellenrieder, Albrecht Neesse
P-MAPS is a European multicentric prospective study. Buccal and rectal swab samples are prospectively collected to analyze the microbiome of acute pancreatitis (AP) patients within the first 72h of hospital admission according to a standardized procedure in 15 European centers in 7 different countries. 400 patients with AP will be initially included in the study, n= 100 with Atlanta II or III. The microbiome is assessed by bedside Oxford Nanopore sequencing technology. We plan to present the current enrollment status, the study protocol, and for the first time preliminary microbiome results from more than 200 analyzed patients.
P2
P2
Patient-reported outcomes three months after pancreatic surgery – a first interim analysis of the German multicenter prospective PS-PROM trial
Meike ten Winkel, Hussein Salama, Orlin Belyaev, Kai Timrott, Dennis Kleine-Döpke, Stefanie Rähder-Johnson, Holger Meisel, Felix Rückert, Schaima Abdelhadi, Kim C. Honselmann, Rüdiger Braun, Steffen Deichmann, Hryhoriy Lapshyn, Tobias Keck, Ulrich F. Wellner, Louisa Bolm
Pancreatic surgery involves complex operative procedures and may have a long-lasting effect on patients’ health status and quality of life. Using patient reported outcomes questionnaires, we evaluated ten dimensions of health-related quality of life, comparing the outcomes 3 months after surgery with the condition prior to surgery.
P4
P4
The Technology of Organ-Saving Endo-Laparoscopic Operations for Uncomplicated ?holecystolithiasis and Gallbladder Polyps
Boris Shevchenko, Oleksandr Babii, Iryna Konenko
The report presents a non-standard technology for the treatment of cholecystolithiasis and gallbladder polyps with organ preservation, which consists in the diagnosis of cholestasis, determination of the cause-and-effect factor in the development of the disease, performing endo-laparoscopic organ-saving operations on the gallbladder according to the developed technique and conducting postoperative rehabilitation
P5
P5
The number of examined lymph nodes, and not only the lymph node involvement, influences survival in resected pancreatic ductal adenocarcinoma
Rüdiger Göß, Carsten Jäger, Julie Perinel, Ilaria Pergolini, Elke Demir, Okan Safak, Florian Scheufele, Stephan Schorn, Mustapha Adham, Helmut Friess, Ekin Demir
Lymph node status is known as one of the most prognostic survival factors in resected pancreatic ductal adenocarcinoma (PDAC). However, the minimal number of examined lymph nodes (eLN) for adequate staging has not yet been established.In our study we demonstrate that not only the lymph node involvement status (N- / N+), but also the number of examined lymph nodes in lymph node negative patients can affect survival in patients with pancreatic cancer.
P6
P6
Perioperative Therapy Concepts in Pancreatic Cancer - A Cross-Validation Of Two National Registries
Natalie Petruch, Louisa Bolm, Sergii Zemskov, Maria Zeller, Taisuke Baba, Jorge Roldan, Jon M. Harrison, Hiroki Sato, Ekaterina Petrova, Hryhoriy Lapshyn, Rüdiger Braun, Kim C. Honselmann, Richard Hummel, Oleksii Dronov, Alexander Kirichenko, Monika Klinkhammer-Schalke, Kees Kleihus-van Tol, Sylke Zeissig, Dirk Rades, Tobias Keck, Carlos Fernandez-del Castillo, Ulrich F. Wellner, Rodney E. Wegner
The cross-validation of the German Cancer Registry Group of the Society of German Tumor Centers and the National Cancer Database demonstrated that strategies of perioperative therapy remain consistent across the registries for stage IA-III pancreatic cancer. Combined neoadjuvant and adjuvant therapy was superior to neoadjuvant therapy alone.
P7
P7
Protein-profiling of liquid biopsies for the differential diagnosis of pancreatic diseases
Thao Vi Nguyen, Thorben Sauer, Kim C. Honselmann, Rüdiger Braun, Katharina Kern, Michael Kohl, Ulrich Wellner, Timo Gemoll
Current differential diagnosis of pancreatic diseases need an invasive, histopathologic examination. Therefore, the development of a liquid biopsy-based method for the differential diagnosis would be an extreme clinical progress. This project compared protein profiles of liquid biopsies between healthy controls and patients with pancreatic diseases (n=83) using LC-MS/MS (liquid chromatography-mass spectrometry/mass spectrometry) in data-independent acquisition (SWATH).The results showed distinct differences in the global protein expression between diverse diseases of the pancreas. Potential protein targets are identified by quantitative mass spectrometry and will be further validated for their biomarker potential.
P8
P8
Second Line and Third Line Therapy with Nanoliposomal Irinotecan (nal-IRI) in pancreatic cancer: A Single Center Experience
Maria Angeles Gonzalez-Carmona, Alexandra Bartels, Freddy Jose Frontado-Graffe, Christian Möhring, Farsaneh Sadeghlar, Taotao Zhou, Robert Mahn, Milka Marinova, Marieta Toma, Georg Feldmann, Peter Brossart, Tim Glowka, Jörg C. Kalff, Christian P. Strassburg
In this retrospective analysis, the use of 5-FU/nal-IRI showed similar antitumoral benefit in an unselected cohort of patients as randomized prospective phase II/III trials. Interestingly, the use of 5-FU/nal-IRI appears to be beneficial as a third line therapy and despite a previous exposition to FOLFIRINOX.
P9
P9
Surgical treatment of complicated pseudocysts of the pancreas
Igor A. Kryvoruchko
The treatment of 505 patients with complicated pseudocysts was analyzed: 81 patients had type I, 247 - type II, and 177 - type III according to the classification of A. D'Egidio and M. Schein. There were consistently used minimally invasive procedures with external drainage under the control of ultrasound and laparoscopy, endoscopic procedures through the stomach or duodenum walls, laparotomy, and laparoscopic internal drainage interventions. The mortality rate was 1.2%.
P10
P10
Laparoscopic Peng’s Binding Pancreaticojejunostomy after Laparoscopic Wipple Prosedure
Gurbankhan Muslumov, Gunay Aliyeva, Natig Zeynalov, Vugar Behbudov
Despite of many types of laparoscopic pancreaticojejunostomy(PJ) have been described in literature, our search for the MEDLINE system did not yield any results on the performing of laparoscopic Peng`s binding PJ. This type of PJ was performed in 3 patients who underwent total laparoscopic PD. These patients were evaluated in terms of operation and PJ formation time, postoperative pancreatic fistula (POPF) rate, postoperative length of hospital stay, postoperative mortality. No pancreatic fistula and mortality were observed in these patients. The median time of the Peng`s PJ was shorter than duct-to-mucosa PJ.
P10a
P10a
Immunotherapy in pancreatic cancer: Effective adjuvant immunotherapy with ipilimumab and nivolumab in patient with microsatellite instability.
Koray Bozkurt, Steffen Deichmann, Louisa Bolm, Kim Christin Honselmann, Rüdiger Braun, Tobias Keck, Ulrich Wellner
One of the clinical major challenges are cancer diseases. Pancreatic cancer is one of the most lethal ending carcinomas, with a sorrowful prognosis within the five-year survival due to late detection and often limited therapy options. Investigating the efficacy and possibilities of immunotherapy are parts of research and considered as therapeutic options. In this case report we will present the effective treatment of checkpoint-inhibitors and monoclonal antibodies in a 50-year-old patient with pancreatic ductal carcinoma.
P11
P11
Open-Label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy with Liposomal Irinotecan Combined with Oxaliplatin and 5 Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patients with Hepatic Oligometastatic Adenocarcinoma of the Pancreas (HOLIPANC)
Florian Gebauer
The HOLIPANC trial is a prospective, single-arm multi center clinical trial investigating the impact of multimodal treatment in hepatic olgiometastsis pancreatic cancer on the overall-survival including complete tumor and metastasis resection.
P12
P12
The gender factor in pancreatic surgery: Are females less susceptible to complications?
Florian Gebauer
In this matched-pair analysis of the StuDoQ database, we could reveal significant sex-related differences between male and female patients with respect to preoperative complications in pancreatic surgery.
P13
P13
Active smokers show ameliorated delayed gastric emptying after pancreatoduodenectomy
Jana Enderes, Jessica Teschke, Martin von Websky, Steffen Manekeller, Jörg C. Kalff, Tim R. Glowka
The effect of smoking on gastric emptying after pancreatoduodenectomy has not yet been investigated in detail. 274 patients were included in the study and analyzed regarding their smoking habits. 35 out of 88 active smokers (40%) and 98 out of 188 non- or former smokers (53%) developed delayed gastric emptying (DGE) (p=0.046) and smokers tolerated solid food intake more quickly than non-smokers (postoperative day 7 vs. 10, p=0.004). Active smokers were less at risk to develop DGE (p=0.051). Our data show that DGE occurs less common in active smokers and they tolerate solid food intake more quickly than non-smokers.
P14
P14
Obesity does not influence delayed gastric emptying following pancreatoduodenectomy
Jana Enderes, Jessica Teschke, Steffen Manekeller, Jörg C. Kalff, Tim R. Glowka
The data about obesity on postoperative outcome after pancreatoduodenectomy (PD) are inconsistent, specifically in relation to gastric motility and delayed gastric emptying (DGE). Thus, patients were analyzed in respect to pre-existing obesity in relation to demographic factors, comorbidities, intraoperative characteristics, mortality and postoperative complications with special emphasis on DGE. We show that clinically relevant DGE grade B/C and specific parameters according to the International Study Group on Pancreatic Surgery were equally distributed. In summary, PD is feasible in the obese patient in regard to postoperative outcome with special emphasis on DGE.
P15
P15
Climate change and its influence on the perioperative morbidity in pancreatic surgery - a heating problem
Florian Oehme, Felix von Bechtolsheim, Sebastian Hempel, Christian Teske, Olga Radulova-Mauersberger, Marius Distler, Jürgen Weitz, Christoph Kahlert
Over the last few decades, the significant impact of climate change on our world, individual countries, economy and society has been a major point of interest for the scientific community. The extent to which this change will also affect our patients is currently completely unclear. The influence of environmental changes on severely ill patients with pancreatic changes requiring surgical resection will therefore be the central question of this study.
P16
P16
Lipasemia in COVID-19-related ARDS
Johanna Erber, Sebastian Rasch, Alexander Herner, Roland M. Schmid, Wolfgang Huber, Tobias Lahmer
Lipasemia is frequent in severe COVID-19, but its pathogenic relevance and aetiology have not been well understood. In this study, clinical and laboratory data of 18 patients with COVID-19 related ARDS and relevant lipasemia were analyzed, showing no typical signs of acute pancreatitis requiring specific treatment.
P17
P17
Loss of muscle mass and strength in experimental chronic pancreatitis
Julia Doller, Matthias Sendler, Frank U. Weiß, Mats L. Wiese, Jens Fielitz, Mihaela Delcea, Solvig Görs, Cornelia C. Metges, Luise Ehlers, Karen Bannert, Robert Jaster, Georg Lamprecht, Markus M. Lerch, Ali A. Aghdassi
We investigated if chronic pancreatitis is associated with sarcopenia in mice. Using two different experimental models we induced chronic pancreatitis in male C57BL6/J mice. In both models a weight loss was observed, that was accompanied by a reduction of the quadriceps muscle diameter and of skeletal muscle strength. Muscles of sarcopenic mice with chronic pancreatitis showed an increase of inhibin A and a decrease of follistatin expression, indicative for increased activin receptor signaling pathways that contribute to sarcopenia.
P18
P18
Progressive intra-abdominal hypertension in the initial stage of acute pancreatitis worsens its prognosis
Ivanna Shchyhel, Olexii Dronov, Inna Kovalska, Andrii Horlach, Fedir Prytkov, Ivanets Tetiana
Aim. To study the effect of changes in intra-abdominal pressure (IAP) in patients with severe acute pancreatitis (SAP).Materials and methods. We examined 295 patients with AP and intra-abdominal hypertension syndrome (IAH). The indicators of IAP and MODS were taken into account on the 3rd - 7th days of the disease.Results. In Group II (41.4%) with positive and neutral ?IAP, there was a higher rate of hospital mortality (p = 0.04), CTSI and infection was associated earlier (p<0.001) then in Group I (58.6%), with a negative ?IAP.Conclusion. Progression of IAH is a factor in the unfavorable outcome of SAP.
P19
P19
Early Surgery for Chronic Pancreatitis
Iurii Mikheiev, Volodymyr Yareshko, Oleh Shpylenko, Dmytro Riazanov
The term of the disease is a major factor of the success of surgical treatment of chronic pancreatitis in terms of long-term results. The early surgery is effective approach to obtain better long-term outcomes in chronic pancreatitis.
P20
P20
Bile acids modulate severity of acute pancreatitis depending on their hydrophobicity
Quang Trung Tran, Matthias Sendler, Ulrich Weiss , Julia Doller, Mats Wiese , Michael Lalk , Uwe Bornscheuer , Markus Lerch, Ali Aghdassi
This project focuses on the impact of bile acids (BAs) in acute pancreatitis when administered systemically. The results elucidate that hydrophobic BAs increase intracellular protease activation in isolated acinar cells but they ameliorate the cell injuring effect of cholecystokinin (CCK) when co-incubating them together. As an underlying effect, we identified that binding of CCK to the CCK1-receptor was decreased when adding BAs.
P21
P21
Propofol in pancreatic cancer surgery: No evidence for its impact on recurrence-free and overall survival
Florian Oehme, André Michalski, Felix von Bechtolsheim, Torsten Richter, Christoph Kahlert
Anesthesiological procedures are important factors that can significantly influence the patient's intraoperative course. The fact that these procedures also have an effect on the oncological results is increasingly suspected. However, scientific analyses and comparative studies are still pending.
P22
P22
Preoperative Ultrasound Elastography (SWE) predicts increased risk of Pancreatic Fistula (POPF) after Pancreaticoduodenectomy
Viktor von Ehrlich-Treuenstätt, Matthias Ilmer, Dirk Clevert, Frederik Klauschen, Steffen Ormanns, Hanno Niess, Jan D'Haese, Martin Angele, Jens Werner, Bernhard Renz
In this prospective study with 100 patients with pancreatic pathologies (71% PDAC), we use ultrasound -based Shear-Wave Elastography (SWE) and Artificial Intelligence (AI) -based Image Data Analysis in Python to correlate stiffness of pancreatic tissue with the occurrence of a clinically relevant POPF. We show that it is a feasible and objective clinical application in predicting pancreatic tissue elasticity. A mean pancreatic elasticity of less than 1.3 m/s was a significant risk predictor of POPF after PD.
P23
P23
Primary patient-derived cell lines of pancreatic ductal adenocarcinoma (PDAC) as preclinical model for intratumor heterogeneity and treatment response
Jessica Watzelt, Olha Lapshyna, Maren Drenckhan, Kim Christin Honselmann, Timo Gemoll, Tobias Keck, Ulrich Friedrich Wellner, Hendrik Ungefroren, Rüdiger Braun
New effective treatment options for pancreatic ductal adenocarcinoma (PDAC) are urgently needed. Dissecting intratumoral clonal heterogeneity by primary single cell-derived cell lines (SCDCLs) of PDAC specimens can serve as a tool to unveil molecular signatures of treatment response. We established and characterized two patient-derived primary PDAC cell lines and developed 16 SCDCLs from one of them, which are currently explored for differential treatment response.
P24
P24
CDKN2A-Mutated Pancreatic Ductal Organoids from Induced Pluripotent Stem Cells to Model a Cancer Predisposition Syndrome
Meike Hohwieler, Jessica Merkle, Markus Breunig, Maximilian Schmid, Chantal Allgöwer, Alexander Kleger
Characterization of the mutational landscape of pancreatic ductal adenocarcinoma is limited to late disease stages, and exploring the complexity of carcinogenic routes is in its infancy. To directly investigate PDAC formation upon specific oncogenic insults, we generated induced pluripotent stem cells (iPSCs) harboring a pathogenic CDKN2A variant and an inducible KRASG12D. KRASG12D expression in differentiated pancreatic duct-like organoids led to structural and molecular changes. After orthotopic transplantation either a high-grade lesion or PDAC-like tumor developed. Hereby, we provide a hereditary human pancreatic cancer model which enables further dissection of early tumor development starting from patient-specific pluripotent stem cells.
P25
P25
The trend of pancreatic cancer in Brazil: 8-year analysis overview
Bruna Oliveira Trindade, Gabriela Rangel Brandão
The aim of this study is to analyze the progression of pancreatic cancer in the Brazilian population from 2013 to 2020 and the demographic data associated with these patients. The data was extracted on the Brazilian healthcare public system database. There were a total of 20,642 cases of pancreatic cancer (1,749 cases in 2013 and 4,169 cases in 2020), being 10,364 male patients. The range of 50 to 69 years old had 60.81% of the total patients. The Southeast was the region that obtained the highest growth rate and the North the lowest growth rate.
P26
P26
Influence of GSK3b on the regulation of DNA damage repair mechanisms in PDAC
Geske Elisabeth Schmidt, Kristina Reutlinger, Aiko Johannes Bockelmann, Karly Conrads, Feda Hamdan, Umair Latif, Sercan Mercan, Marius Brunner, Hanibal Bohnenberger, Gabriela Salinas-Riester, Philipp Ströbel, Elisabeth Hessmann, Steven Arthur Johnsen, Volker Ellenrieder, Elisabeth Tan
In this study, we address the role of GSK3b, a characteristic protein of the highly aggressive basal PDAC subtype. We aimed to understand its influence on gene expression and the resulting effects on chemotherapy responsiveness. Our study revealed that GSK3b targets DNA damage mechanisms. Moreover, we could identify NFATc1 as one of the downstream leading transcription factors. NFATc1 is stabilized by GSK3b, thus GSK3b inhibition leads to reduced levels of NFATc1 and the downregulation of several DNA damage gene signatures. Therefore, we conclude that GSK3b inhibition causes sensitization towards chemotherapy by targeting the DNA damage response via NFATc1.
P27
P27
Identification of molecular signatures for response of pancreatic ductal adenocarcinoma to chemotherapeutic agents for therapy stratification using clonal cell culture models
Benedikt Färber, Kira M. Bichmann, Olha Lapshyna, Timo Gemoll, Thorben Sauer, Hendrik Ungefroren, Tobias Keck, Ulrich Wellner, Rüdiger Braun
Intratumoral heterogeneity (ITH) might be an important aspect for treatment response in pancreatic cancer. Using single cell derived cell lines (SCDCLs) from four established cell lines, we uncovered ITH within the parental tumor cell population. Our experimental approach shows that each of the analyzed parental tumor cell population is composed of many distinct subclones with different resistance profiles to gemcitabine. These subclones differ in specific transcriptomic and proteomic aberrations, which presumably will allow stratification and individual therapy adaptation to overcome clone specific treatment resistance.
P29
P29
Selective elimination of cancer stem cells as therapy for PDAC using novel dual BET/HDAC inhibitor TW09
Kanishka Tiwary, Arijan Valar, Selina Mader, Stefanie Hauff, Tabea Dittrich, Xin Zhang, Eva Rodriguez-Aznar, Alexander Kleger, Thomas Seufferlein, Bruno Sainz Jr, Jens T. Siveke, Karolin Walter, Patrick C. Hermann
This study demonstrates the therapeutic potential of novel dual BET/HDAC inhibitor TW09 in a preclinical set-up. Deregulation of different molecular pathways involved in cancer stem cell maintenance, pluripotency and EMT using TW09 is elucidated.
P30
P30
Antibiotic resistence patterns of bacterial bile cultures during pancreatic surgery – A single center analysis and systematic review
Benjamin Müssle, Felix Bechtolsheim, Carolin Marx, Florian Oehme, Sebastian Hempel, Andreas Bogner, Christoph Kahlert, Marius Distler, Jürgen Weitz, Thilo Welsch
Septic complications after pancreatic surgery are common. It remains unclear if and how a shift of the bacterial spectrum affects morbidity after pancreatic surgery. Retrospective study and systematic review.Patients with biliary drainage had a significantly higher incidence of bacterobilia and preoperative antibiotics. Analyzed bile cultures showed no resistance to piperacillin/tazobactam, fluoroquinolones and carbapenems. Cefuroxime had a resistance in 93% of bile samples of BD-patients. Almost all studies demonstrated a resistance to second generation cephalosporins and against 3. and 4. generation cephalosporins for patients with BD. Appropriate perioperative antibiotic coverage may help to prevent abdominal infectious complications especially wound infections.
P31
P31
Characterization of therapeutic strategies for the treatment of ARID1A-deficient pancreatic cancer
Maira Volland, Theresa Waßmann, Maria Ulisse, Zhe Zhang, Lennart Versemann, Jessica Spitalieri, Katherina Ewers, Matthias Dobbelstein, Shiv K. Singh, Laura Urbach, Lukas Klein, Elisabeth Hessmann
The tumor suppressor AT-rich interactive Domain-containing protein 1A (ARID1A) is the most frequently mutated member of the SWI/SNF chromatin-remodelling complex in PDAC. ARID1A-deficiency promotes the up-regulation of inflammation-associated gene sets including inflammatory transcription factors (e.g. NFATc1, NFkB, STAT3) leading to a more aggressive and dedifferentiated PDAC phenotype. As increased levels of the activated inflammatory transcription factors can be detected in ARID1A-deficient cells and tumor tissue, their targeting seems to be a promising strategy to tackle this PDAC subtype. We tested different inhibitors and could interestingly see beneficial effects. We than further investigated the background and the mechanism of action.
P32
P32
Chronic Lipopolysaccharide exposure promotes KrasG12D-induced pancreatic carcinogenesis
Zhenhua Huang, Frank Bergmann, John Neoptolemos, Thilo Hackert, Franco Fortunato
The role of Lipopolysaccharides (LPS) in influencing PDAC tumorigenesis and progression is still unclear. We aimed to investigate the relationship between LPS and tumorigenesis in a mouse model of pancreatic precancerous lesions. LSL-KrasG12D; Ptf1a/p48-cre mice were treated with LPS at the life-threatening dose of 2 mg/kg biweekly by intraperitoneal injection for 7 weeks from 25 weeks age. KrasG12D-induced pancreas tumorigenesis was augmented by LPS treatment through the activation of autophagy and the attenuation of apoptosis and necroptosis. Also, Chronic LPS exposure stimulated the secretion of pro-inflammatory cytokine IL-1? from PDAC cells and may promote PDAC progression.
P33
P33
An in ovo system to study tumor morphogenesis and metastatic dissemination of pancreatic cancer patient-derived organoids
Raphela Ranjan, Katja Steiger, Roland Schmid, Maximilian Reichert
We optimized a protocol to establish the CAM as a PDO-on-CAM model. To that end, we successfully engrafted six different patient-derived organoid (PDO) lines, isolated from surgical biopsy or fine needle aspiration/biopsy. Tumors form within a span of five days Importantly, the PDO-on-CAM tumors recapitulated the histomorphological features of the primary tumors from the PDAC patients. The experiment is terminated on day 14 and chick embryo organs, specifically the brain, heart, and liver, were collected. Spontaneous metastases of the PDOs were determined by quantitative PCR (qPCR) of Alu sequences.
P34
P34
Deciphering the role of the EZH2 epigenetic factor in ATM-deficient pancreatic cancer progression
Elodie Roger, Luise Goldfuß, Johann Gout, Lukas Perkhofer, Thomas Seufferlein, Alexander Kleger, Elisabeth Heßmann
Pancreatic ductal adenocarcinoma (PDACs) are aggressive cancers characterized by a heterogeneous mutational landscape which leads to the importance of molecular stratification to develop tailored therapies. We reported that the loss of the DNA damage response gene ATM serine/threonine kinase in PDAC is correlated with aggressive features, including invasive properties. Interestingly, we reported increased expression of the EZH2 epigenetic factor as a critical event in ATM-deficient PDAC plasticity and progression, and we therefore suggest that ATM tumoral status may specifically redraft tumoral epigenetic landscape.
P35
P35
Proteome Biology of the Residual PDAC Tumor Mass after Neo-adjuvant Treatment: Comparing Chemo- and combined Chemo-radiation Therapy
Maren Stillger, Sylvia Timme-Bronsert, Peter Bronsert, Martin Werner, Laura Tang, Oliver Schilling
Treatment strategies for PDAC patients are controversial and the benefit of combined neo-adjuvant chemo and radiation therapy is debatable. We investigated the proteomes of residual PDAC after neo-adjuvant treatment and discovered explicit biological differences. While there was a strong increase of ribosomal proteins and the citric acid cycle after neo-adjuvant chemotherapy, we observed an increase of the complement and coagulation cascade as well as of extracellular matrix components after chemo-radiation. In the investigated cohort, a competitive risk analysis revealed a significantly decreased incidence of death in patients who underwent neo-adjuvant chemo-radiation therapy when compared with patients who underwent neo-adjuvant chemotherapy.
P36
P36
Major postoperative complications increase tumor recurrence rate and diminish long-term survival following resection for pancreatic ductal adenocarcinoma
Andreas Andreou, Pauline Aeschbacher, Anna Wenning, Daniel Candinas, Beat Gloor
Major complications have been associated with worse oncologic outcomes following resection for several gastrointestinal malignancies. However, the impact of major postoperative morbidity on the survivals of patients undergoing resection for pancreatic ductal adenocarcinoma (PDAC) remains unclear. We evaluated the disease-free and overall survival of patients suffering a major postoperative complication in comparison to those of patients without any major postoperative adverse events in univariate and multivariate analysis. Major postoperative complications promote tumor recurrence following resection for PDAC, thus limiting long-term survival. Careful patient selection and optimized complication management may reduce postoperative morbidity, thereby lowering its negative impact on oncologic prognosis.
P37
P37
Characterization of p53-status dependent EZH2 Activity in Pancreatic Cancer Progression and Treatment
Lennart Versemann, Shilpa Patil, Zhe Zhang, Waltraut Kopp, Christin Kellner, Volker Ellenrieder, Elisabeth Hessmann
Pancreatic Ductal Adenocarcinoma (PDAC) remains a devastating disease with an overall 5-year survival rate of less than 10%. A major reason for the high mortality rates of PDAC is the resistance to conventional chemotherapy caused by cellular plasticity installed by epigenetic alterations. The histone methyltransferase EZH2, a member of the Polycomb-Repressor-Complex 2, is regularly found overexpressed in PDAC and plays a significant role in the evasion of apoptosis, senescence, and DNA damage repair. However, recent reports suggest a strong context-dependency of onco-genic EZH2 activity.
P38
P38
Longitudinal characterization of primary cells derived from PDAC Patient-Derived-Xenograft models
Charlotte Sigg, Karly Conrads , Christin Kellner, Waltraut Kopp, Jennifer Appelhans, Mark-Sebastian Bösherz, Elisabeth Heßmann
Different preclinical models were established to study PDAC, e.g. patient derived xenograft (PDX) and PDX-derived cell lines (CDX). To what extent CDX lines reflect the molecular patterns of the primary tumour and how these characteristics are conserved in culture remains elusive. Therefore, we established a highly standardized protocol for longitudinal characterization of multiple PDAC CDX lines regarding morphology, genetic alterations, genome-wide gene- and targeted protein expression. While CDX cells seem to reflect genetic characteristics of the donor tumours, we observe distinct gene expression profiles in CDX- compared to PDX models and a dynamic regulation of gene expression over time.
P39
P39
Hdac2 facilitates pancreatic cancer metastasis
Lukas Krauß, Bettina Urban, Sieglinde Hastreiter, Carolin Schneider, Patrick Wenzel, Zonera Hassan, Matthias Wirth, Katharina Lankes, Andrea Terasi, Christine Clement, Filippo Cernilogar, Rupert Öllinger, Niklas de Andrade Krätzig, Thomas Engleitner , Roland Schmid, Katja Steiger, Roland Rad, Oliver Krämer, Maximilian Reichert, Dieter Saur, Gunnar Schotta, Günter Schneider
The epigenetic eraser histone deacetylase 2 (HDAC2) has been connected to less differentiated PDAC, but the function of HDAC2 in PDAC has not been comprehensively evaluated. Using genetically defined models, we show that HDAC2 is a cellular fitness factor that controls cell cycle in vitro and metastasis in vivo, particularly in undifferentiated, mesenchymal PDAC cells. HDAC2 controlled expression of receptor tyrosine kinases connected to mesenchymal PDAC, including PDGFR?, PDGFR?, and EGFR disabled the tumor-suppressive arm of the TGF?-pathway, explaining impaired metastasis formation of HDAC2-deficient PDAC. This data identifies HDAC2 as a tractable player in the PDAC metastatic cascade.
P40
P40
Identification of the Neurokinin-1 Receptor as targetable strat-ification factor for drug repurposing in Pancreatic Cancer
Iris Beirith, Bernhard W. Renz, Shristee Mudusetti, Natalja S. Ring, Julian Kolorz, Dominik Koch, Alexandr V. Bazhin, Michael Berger, Jing Wang, Martin K. Angele, Jan G. D'Haese, Markus O. Guba, Hanno Niess, Joachim Andrassy, Jens Werner, Matthias Ilmer
Targeting the neurokinin-1 receptor with small molecules has previously shown anti-tumoral ef-fects in a large variety of cancers. Here, we found specific types of pancreatic cells to express the neurokinin-1 receptor while at the same time showing positive treatment response represented by cell growth reduction in number and size when treated with aprepitant. Our results suggest the neurokinin-1 receptor as a new promising targetable structure and therefore interesting in the concept of personalized medicine.
P41
P41
Spatially targeting pancreatic cancer to enhance local treatment efficacy and allow systemic immune response
Kornelia Aigner, Yogesh Vashist, Karl Reinhard Aigner
A feasible surgical technique is described for spatially targeting pancreatic cancer with high drug concentrations while keeping systemic effects low. Upper Abdominal Perfusion (UAP), performed as a two step method with a stopped flow phase and a perfusion phase reaches extremely high drug concentrations at the tumor site despite low total drug dosages. Tumor necrosis is reached by these high drug concentrations which can lead to systemic immune responses and change the tumor immunogenic characteristics of the tumor. This might be a more beneficial basis for molecular targeting and immuno therapies.
P42
P42
The lymph node ratio correlates with parameters of aggressive biology and is a strong and independent prognostic factors ampullary cancer – a retrospective bicentric study
Miljana Vladimirov, Lisa Blankenhorn, Kerstin Moskorz, Myriam Neininger, Thomas Papadopoulos, Hubert Stein, Ulrich Wellner, Tobias Keck, Dirk Bausch, Louisa Bolm, Meike ten Winkel, Steffen Deichmann, Kim Honselmann
Ampullary cancer is a rare disease characterized by relatively good prognosis after resection. Several prognostic factors have been described, and attempts are being made to identify predictive parameters for adjuvant chemotherapy. This study aimed at investigating the prognostic role of the lymph node ratio (LNR) and its biologic implications in ampullary cancer.
P43
P43
Role of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic cancer
Silje Beckinger, Leon Aldag, Sandra Krüger, Steffen Heckl, Christoph Röcken, Susanne Sebens
Pancreatic ductal adenocarcinoma is a rare cancer representing the 7th common cause of cancer related death. Most patients are diagnosed at an advanced stage, showing liver metastases. Targeting the immune checkpoint regulator programmed cell death protein 1-ligand 1 (PD-L1) is a promising therapy for several cancers but failed in PDAC yet. Therefore, this study aimed to better understand the impact of the liver microenvironment on PD-L1 in PDAC. Compared to primary PDAC, liver metastases exhibited elevated PD-L1 expression, which was confirmed in 3D cocultures of PDAC cells and hepatic myofibroblasts. Ongoing studies explore the therapeutic efficacy of different treatment combinations.
P44
P44
Phenotypic and molecular characterization of duct- and acinar-derived pancreatic ductal adenocarcinoma
Jingxiong Hu, Yuanyuan Yu, Kathleen Schuck, Christoph Michalski, Andre Mihaljevic, Bo Kong
Previous studies have demonstrated that cell of origin affects pancreatic ductal adenocarcinoma (PDAC) subtype specification. Using transgenic mouse models, we confirmed oncogenic Kras in combination with p53 deletion and caerulein- and ductal ligation-induced pancreatitis can drive PDAC development from ductal and acinar cells. Survival analysis showed that mice with duct-derived tumor had a longer survival than those with acinar-derived tumor. Despite the similarity of in major oncogenic signaling, acinar-derived tumor exhibited more desmoplastic stroma compared with duct-derived tumor.
P45
P45
Investigating dynamic crosstalks between cancer-associated fibroblasts and tumor cells in ATM-deficient pancreatic cancer
Elodie Roger, Frank Arnold, Eleni Zimmer, Dharini Srinivasan, Lukas Perkhofer, Thomas Seufferlein, Johann Gout, Alexander Kleger
Pancreatic ductal adenocarcinoma (PDACs) are aggressive cancers with a dense tumor stroma, in which complex tumor/stroma crosstalks, including cancer-associated fibroblast (CAF), are dynamically involved in tumor progression. We reported that the loss of the DNA damage response gene ATM serine/threonine kinase in pancreatic tumor cells may specifically reshape tumor microenvironment and especially CAF content. Interestingly, in vivo, and in vitro approaches revealed that high levels of TGF?1 secreted by ATM-depleted tumor cells are correlated with specific myofibroblastic CAF differentiation, which may in turn promote extended desmoplastic reaction and finally support tumor aggressiveness.
P46
P46
Neoadjuvant chemotherapy suppresses immune function and favours neuronal activity in patients with pancreatic ductal adenocarcinoma
Maximilian Kießler, Carmen Mota-Reyes, Helmut Friess, Rouzanna Istvanffy, Ihsan Ekin Demir
Neoadjuvant therapy is an important treatment modality in patients with pancreatic ductal adenocarcinoma (PDAC), but little is known about changes in genetic pathways in the tumor microenvironment induced by neoadjuvant chemotherapy. We therefore performed a comparative whole tissue mRNA sequencing analysis on tissue gathered from PDAC patients who underwent either primary resection or neoadjuvant chemotherapy followed by resection, and analysed it for differential gene expression, gene set enrichment analysis and cell type enrichment analysis. Our results show that the lymphoid and myeloid immune response in neoadjuvantly treated PDAC patients is significantly suppressed, and neuronal remodeling is increased.
P48
P48
Characterization of the mechanistic and functional implications of ARID1A deficiency in inflammation and tumor-promoting processes in PDAC
Maria Ulisse
The SWitch/Sucrose Non-Fermentable (SWI/SNF) complex, and in particular its AT-rich interaction domain-containing protein 1A (ARID1A) subunit is frequently mutated in pancreatic ductal adenocarcinoma (PDAC). Our findings link Arid1a loss to PDAC dedifferentiation and tumor progression in vivo. ChIP-seq analysis unveiled ARID1A binding mostly at distal/enhancer regions linked to inflammatory genes. Interestingly, RNA-seq analysis revealed upregulation of these inflammation/tumor-associated gene sets upon ARID1A-deficiency. Further, our findings suggest that ARID1A-deficiency promotes transcriptional reprogramming processes mediated by inflammatory tumor-promoting transcription factors. Together, our findings suggest that ARID1A deficiency plays a crucial role in PDAC via fostering inflammation and tumor progression.
P49
P49
The impact of Tenascin-C in lung metastases of pancreatic cancer
Friederike Opitz, Alexandra Daum, Martin Schlensog, Aslihan Yavas, Lena Häberle , Sandra Biskup, Irene Esposito
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy. PDAC tend to develop fibrous tissue, which contains increased amounts of the metastasis-promoting glycoprotein tenascin-C (TNC). The impact of TNC in lung metastases of PDAC was investigated using mice with TNC-wildtype or knockout genotype. Our studies reveal that TNC-knockout mice tend to have more numerous metastases, which additionally show increased protein expression of TNC, selectins and integrins. Moreover, mRNA expression of actin-regulating genes and integrins was enhanced in tumor cells incubated in TNC-knockout media. Taken together, our data demonstrate that TNC potentially promotes metastasis in an autocrine and/or paracrine manner.
P50
P50
Intraabdominal hypertension as a risk factor of gastrointestinal fistula formation in patients with severe acute pancreatitis
Olexii Dronov, Inna Kovalska, Andrii Horlach, Tetiana Ivanets, Ivanna Shchyhel, Fedir Prytkov
Introduction. The incidence of intraabdominal hypertension(IAH) and abdominal compartment syndrome(ACS) in patients with acute pancreatitis(AP) is 50-60% and 8-27% respectively. IAH was associated with bowel ischemia and gastrointestinal fistula(GIF) formation. Aim: to identify the influence of prolonged IAH on GIF formation. Methods. Statistical analysis of 122 severe AP cases with prolonged IAH. Results. From 122 patients with prolonged IAH 7 (5%) were diagnosed with GIF(p<0.01). Conclusion. Prolonged IAH may be a risk factor of GIF formation (p<0,01). Intestines’ damage may be associated with IAH, due to hypovolemia, splanchnic vasoconstriction and microthrombosis. Untreated IAH may lead to GIF formation.
P51
P51
Experience in the use of pancreatogastroanastomosis at the reconstructive stage at a pancreatoduodenectomy.
Bohdan Tsubera
The problem of malignant neoplasms of the biliopancreatoduodenal area is becoming increasingly important due to the steady increase in the incidence of this pathology. According to GLOBOCAN 2020, pancreatic cancer in the structure of the total incidence in the world - ranks 12th and is 2.6%. Regarding the structure of total mortality - 4.7%, ranking 7th among the causes of cancer mortality in the world. The incidence of pancreatic cancer is 4-9 people per 100 thousand population.
P52
P52
Synergic crosstalk between intratumoral nerves and myeloid derived suppressor cells in pancreatic cancer via neuronal-derived expression of CXCL8
Carmen Mota Reyes, Teresa Zwick, Kaan Cifcibasi, Alexander Muckenhuber, Wilko Weichert, Helmut Friess, Hana Algül, Ruzanna Istvanffy, Ihsan Ekin Demir
MDSC mediate T-cell immunosuppression and correlate with worsened prognosis in pancreatic cancer (PCa). Here, we demonstrated that PCa-invaded nerves attract MDSCs into the perineural niche via secretion of CXCL8 and that MDSC in the vicinity of intrapancreatic nerves promote in turn, perineural cancer spread. MDSC density was higher on patients with severe neural invasion (NI) and around tumor-invaded nerves. The migration of PCa cells towards neurons was enhanced by MDSC, leading to increased CXCL8-secretion, a known MDSC-chemoattractant. Furthermore, the expression of CXCL8 was upregulated on PCa-invaded nerves. Thus, CXCL8 constitutes an attractive therapeutic target for decreasing pancreatic NI.
P53
P53
The porcine urinary bladder mimics a pancreatic niche and enables cancer modelling
Michael Karl Melzer, Markus Breunig, Frank Arnold, Felix Wezel, Anca Azoitei, Elodie Roger, Jana Krüger, Jessica Merkle, Lena Schütte, Friedemann Zengerling, Ninel Azoitei, Thomas Seufferlein, Meike Hohwieler, Christian Bolenz, Cagatay Günes, Johann Gout, Alexander Kleger
Organ culture models have proven to be of high value for stem cell lineage commitment and organ recapitulation in vitro. Here, we establish the porcine urinary bladder (PUB) as an organ culture model for shaping a pancreatic niche. Pluripotent stem cell-derived pancreatic progenitors and duct-like organoids (PDLOs) display enhanced maturation on-PUB. Featuring oncogenic KRASG12D within PDLOs leads to papillary tumor growth on-PUB. Finally, pancreatic cancer patient-derived organoids in combination with stromal and immune cells on-PUB enable the mimicry of PDAC ex vivo and enhance the options to study epithelial-stroma crosstalk.
P54
P54
Single cell analysis of primary isolated and cultured pancreatic cancer-associated fibroblasts
Yoshiaki Sunami, Luca Tosti, Matthias Sommerer, Jörg Kleeff
Cancer-associated fibroblasts (CAFs) play a major role in the progression and drug resistance of pancreatic cancer. Recent studies suggest that CAFs exhibit functional heterogeneity with distinct gene expression profiling in pancreatic cancer. In this study, we used CAFs primary isolated from pancreatic cancer patients and chronic pancreatitis patient via outgrowth method to see whether we can detect previously described myCAF and iCAF clusters in patient specimens, and whether we can identify novel CAF subtypes potentially associated with pancreatic diseases development or progression.
P55
P55
Characterizing stromal subtypes in patient-derived Xenograft Models of Pancreatic Cancer
Louisa Bolm, Natalie Petruch, Pascal Finetti, Andrew L. Warshaw, Carlos Férnandez-Del Castillo, Andrew S. Liss
A dense desmoplastic stroma in pancreatic ductal adenocarcinoma (PDAC) promotes tumor progression and cancer cell invasion. Patient-derived xenograft (PDX) models have been used to investigate PDAC tumor biology. Systematic characterization of the stromal component in PDX models demonstrated four distinct stromal subtypes providing an opportunity to investigate subtype-specific response to stroma-targeted therapies
P56
P56
Short and long-term outcomes of surgical treatment of resectable and borderline resectable pancreatic adenocarcinoma
Yevhenii Trehub, Oleg Vasiliev
A total of 188 patients surgically treated for non-metastatic pancreatic adenocarcinoma in National Cancer Institute, Kyiv, Ukraine in 2015-2021 were retrospectively analyzed. Concomitant portal/mesenteric vein resection was performed in 67. Short-term outcomes were analized in terms of major morbidity, postoperative, 30- and 90-day mortality. Long-term outcomes were asessed as overall survival. Comparative analyzes between standart pancreatectomy and venous resection groups were performed.
P57
P57
Transcriptomic landscape of human epithelial and stromal cells purified from cancer and normal tissue dissects cross-talks and deregulated signaling in PDAC
Elisa Espinet, Zuguang Gu, Jing Yang, Nathalia A Giese, Vanessa Vogel, Thilo Hackert, Oliver Strobel, Matthias Schlesner, Wilko Weichert, Martin Sprick, Andreas Trumpp
To better understand the specific signals and interactions taking place in and between different tumor compartments in human pancreatic cancer, we have derived a comprehensive trancriptomic landscape of purified cell-type population from a collection of more than 30 primary tumors and normal pancreas. The generated data uncovered a profound transcriptomic reprogramming in all cancer populations versus normal counterpart. Distinct deregulations occurred in specific subsets of patients unveiling potential personalized targeted therapies.
P58
P58
Interleukin-13-receptor-alpha-1 plays a crucial role in pancreatic cancer progression
Qi Kang, Jingwei Shi, Christoph Michalski, Marko Kornmann, Benno Traub
Interleukin (IL)-4 and IL-13 are supposed to exert effective effects in pancreatic cancer through the specific receptor complex IL-4-receptor-? (IL-4R?)/IL-13R?)1.While IL-4 and IL-4R? were shown to be tumor-promoting in PDAC, the specific role of the IL-13/IL-13R?1 axis was yet to be determined. IL-4 and IL-13 axes may be successfully used in the treatment of pancreatic cancer.In this project, we planned to figure out the specific effects of the IL-13R? 1-receptor chain on the malignant phenotype of pancreatic cancer cells.
P59
P59
Increased frequencies of IL3 producing memory B cells in lymph node 8a of pancreatic ductal adenocarcinoma patients
Paul David, Frederik Hansen, Anke Mittelstaedt, Anne Jacobsen, Malgorzata Podolska, Dina Kouhestani, Maxilillian Brunner, Christian Krautz, Robert Gruetzmann, Alan Benard, Georg Weber
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with one of the lowest 5-year survival rates of all solid tumors. Lymph node 8a has prognostic value for predicting severity in PDAC patients. One major cellular compartment of lymph nodes are CD20+ B cells, In this study, we phenotype B cells in lymph node 8a (LN8a) of PDAC patients and lymph node 12b (LN12b) of patients undergoing laparoscopic cholecystectomy serving as controls. LN8a from PDAC patients had significantly increased CD20+ B cells, IL3-producing B cell and significantly higher expression of IgD in comparison to LN12b.
P60
P60
The immunogenic phenotype triggered by acquired PARP-inhibitor resistance in ATM-deficient pancreatic cancer cells
Frank Arnold, Elodie Roger, Thomas Seufferlein, Johann Gout, Alexander Kleger
Unstable PDAC subtype is characterized by mutations in DNA damage response (DDR) genes with ATM as the most frequently mutated gene. This subtype shows increased sensitivity towards PARP inhibition (PARPi). Unfortunately, these tumor cells develop early resistance to single PARPi, rendering them resistant to any given second-line treatment strategies. Here, we report that ATM-deficient PDAC resistant to PARPi showed pronounced expression of MHC class I receptor, caused by acquired genetic alterations indicative for neoantigens. Thus, these data suggest that PARPi-resistant tumor cells are putatively vulnerable for T cell-mediated tumor killing, which can be used to overcome resistance.
P61
P61
Pancreatic resection with perioperative drug repurposing of propranolol and etodolac: the phase-II randomised placebo controlled PROSPER trial
Felix J. Hüttner, Ilse Rooman, Gauthier Bouche, Oliver Strobel, Phillip Knebel, André L. Mihaljevic, Thilo Hackert, Markus W. Büchler, Markus K. Diener
The combination therapy of propranolol and etodolac in the perioperative setting surrounding resection of pancreatic cancer promises an effective attenuation of tumor-associated inflammation by inhibiting psychological, surgical and inflammatory stress responses. The PROSPER trial was a single-center, double blind, randomized, placebo-controlled phase-II trial evaluating safety and feasibility of combined perioperative treatment with propranolol and etodolac in adult patients with non-metastatic cancer of the pancreatic head undergoing elective partial pancreatoduodenectomy. The trial objective was the assessment of safety, feasibility and to generate first efficacy data.
P62
P62
DIAGNOSTICS OF THE POST-TRAUMATIC PANCREATITIS
Olena Babkina, Svitlana Danylchenko
In case of abdominal trauma, one of the evidence-based and informative research methods is ultrasound diagnostics, with the help of which it is possible to conduct a consistent and thorough examination of internal organs, in particular the pancreas (post-traumatic pancreatitis), liver, spleen, kidneys, both in order to identify the presence and nature of damage, and in order to diagnostics of the prescription of their occurrence.
P63
P63
Chronic liver disease increases mortality following pancreatoduodenectomy
Jana Enderes, Jessica Teschke, Steffen Manekeller, Tim O. Vilz, Jörg C. Kalff, Tim R. Glowka
The effect of smoking on gastric emptying after pancreatoduodenectomy has not yet been investigated in detail. 274 patients were included in the study and analyzed regarding their smoking habits. 35 out of 88 active smokers (40%) and 98 out of 188 non- or former smokers (53%) developed delayed gastric emptying (DGE) (p=0.046) and smokers tolerated solid food intake more quickly than non-smokers (postoperative day 7 vs. 10, p=0.004). Active smokers were less at risk to develop DGE (p=0.051). Our data show that DGE occurs less common in active smokers and they tolerate solid food intake more quickly than non-smokers.
P64
P64
Impact of Sample Storage on the Serum Proteome Quality
Thorben Sauer
Large sample numbers are crucial for biomarker research. Therefore, samples have to be stored until they are used for analysis what makes sample quality assessment necessary. We studied the impact of sample storage on the serum proteome quality of patient serum samples
P65
P65
How to predict microlithiasis in idiopathic pancreatitis - a machine learning derived tool
Micha? ?orniak, Simon Sirtl, Eric Hohmann, Julia Mayerle, Ujjwal Mahajan
We present a robust machine-learning-based predictor consisting of routinely recorded parameters at admission that can predict microlithiasis as a cause of pancreatitis.
P66
P66
SBPC Chronic Pancreatitis Registry: results of an database structure implementation at the University Medical Center Schleswig Holstein, Campus Lübeck
Natalie Frenzel, Meike ten Winkel, Rüdiger Braun, Louisa Bolm, Steffen Deichmann, Kim Honselmann, Hryhoriy Lapshyn, Tobias Keck, Ulrich Wellner
The Scandinavian baltic pancreatic club database was founded to gain new insights into the development and course of chronic pancreatitis.In the Department of Surgery at the University Hospital of Lübeck, about 30 patients suffering from chronic pancreatitis are treated every year. Due to the complexity of the disease, the patients are usually cared for over many years, which has already resulted in a large amount of data.The database could form a basis for future observational studies, from which new insights into the course of treatment and the quality of life of patients could be gained.
P67
P67
The embryonic transcription factor Tbx3 fine-tunes regeneration from acute pancreatitis
Michael Karl Melzer, Frank Arnold, Johann Gout, Silvia Schirge, Cagatay Günes, Christian Bolenz, Thomas Seufferlein, Lukas Perkhofer, Alexander Kleger
T-Box Transcription Factor 3 (Tbx3) acts as a dynamic switch in activation of pluripotency, and thus stem cell renewal. Re-activation of genetic programs from early development is vital for injury-induced organ regeneration.We demonstrate that Tbx3 switches expression patterns during embryonic development and is absent in adult pancreas. Interestingly, induction of acute pancreatitis leads to re-activation of Tbx3 expression. Furthermore, we observed a delayed pancreatic regeneration after acute pancreatitis in p48-Cre depleted Tbx3 knockout mice, resulting in a higher fibrotic content and proliferation rate.This may indicate that Tbx3 favors tissue development and repair through regulation of stem cell compartments.
P68
P68
Results of treatment fluid collections in acute pancreatitis using minimally invasive procedures
Igor A. Kryvoruchko
176 patients were analyzed with symptomatic sterile and infected pancreatic and peripancreatic fluids collections with diameters greater than 6 cm: in 87 were used one, in 68 two and in 21 three plastic stents due in presence of multiple collections. A positive effect manifested by the lacked early mortality. However, adverse events occurred more frequently in patients who had two or more plastic stents, but direct comparison between the two groups showed that the difference was not statistically significant (p=0.32).109 (61.8%) of them necrosectomy due secondary infections were done on within 3-4 weeks. Mortality was 8.5%.
P69
P69
Retrospective study of routine laboratory indices in patients with necrotizing pancreatitis in the prospect of their use for the timing of operative pancreatic debridement
Yaroslav Susak, Oksana Lobanova, Mykhailo Maksymenko, Larysa Skivka, Olexandr Tkachenko, Illia Tiuliukin
A retrospective analysis of dynamic changes of conventional hematological and biochemical indices were examined in preoperative period. 48 participants (90.6%) were diagnosed with MSAP, 5 (9.4%) - with SAP. Median postoperativeLOS was of 36 days. Mortality was about 19%. Progressive increase in PLT count in preoperative period, which correlated with shortened total hospitalLOS, can indicate granulation tissue formation, and can be regarded as additional marker for OPDtiming. Slight progressive decrease of DB along with increased AST serum level indicate persistent hepatic malfunction, and can be regarded as an additional marker of high risk of post-operative mortality in ANP patients.
P70
P70
Colocalization of pancreas eQTLs with risk loci from alcoholic and novel non-alcoholic chronic pancreatitis GWAS reveals disease causing mechanisms
Andreas W. Schmidt, Andreas Kühnapfel, Holger Kirsten, Heiko Witt, Helmut Laumen, Jonas Rosendahl
We conducted a GWAS in 584 non-alcoholic chronic pancreatitis (NACP) patients and 6040 healthy controls. Variants at the CTRC and SPINK1 risk loci were genome-wide significantly associated with NACP. Next, we applied Bayesian colocalization analysis on discovered genome-wide significant loci from both, our recently published alcoholic chronic pancreatitis (ACP) GWAS and the novel NACP dataset, with pancreas eQTLs from GTEx, to discover disease causing variants and genes. We found CTRC and CLDN2-MORC4 variants presumably causing chronic pancreatitis by altering expression of CTRC and CLDN2, respectively. Moreover, in the ACP locus PRSS1-PRSS2 we identified variants modifying expression levels of TRBV29-1.
P71
P71
Endoscopic ultrasonography(EUS)-guided drainage of the pancreatic duct (EU-PD) to treat symptomatic retention pancreatitis - a minimally invasive alternative of surgical re-intervention in patients with altered anatomy of the upper GI tract
T. Buechner
P72
P72
Comparative analysis of DNA mutations in PDAC tumors and corresponding cf-/evDNA liquid biopsy samples upon panel sequencing
Mareike Waldenmaier, Mareen Morawe, Tim Eiseler, Thomas Seufferlein
PDAC diagnosis and treatment is increasingly informed by personalized medicine approaches utilizing next generation sequencing of tumor biopsy and liquid biopsy samples. Our study has investigated DNA mutational profiling detected by panel sequencing of ev- and cfDNA in respect to tumor biopsy material. We show that evDNA contains significantly longer fragment sizes and was able to more precisely reflect mutations detected in tumorDNA compared to cfDNA analysis. Thus, evDNA may be helpful and beneficial to extend and support mutational analysis in patients for diagnosis and treatment.
P73
P73
Hamburg Glasgow Classification for Pancreatic Cancer
Thaer S. A. Abdalla, Matthias Reeh, Jakob R. Izbicki
Despite the great achievements in pancreatic cancer, identification of patients who will suffer rapid disease relapse and progression is not perfect, especially when definitive histology for tumor staging is not available. The Hamburg Glasgow Classification combines tumor cell dissemination in the bone marrow and systemic inflammatory response into a preoperative staging system. In this work, we assessed the Hamburg Glasgow Classification in potentially resectable pancreatic cancer as a prognostic classification for overall and progression-free survival and compared it to UICC-TNM classification with promising results.
P74
P74
Liquid Biopsy For Monitoring Pancreatic Cancer Recurrence
Teresa Colbatzky, Ulrike Heger, Fawaz Al-Shaheri, Lucas Sperling, Christin Tjaden, Ulf Hinz, Nathalia Giese, Thilo Hackert, Jörg Hoheisel
In prospectively collected serum samples we aimed to validate a retrospectively determined protein panel fordiagnosis of recurrence in pancreatic ductal adenocarcinoma (PDAC) patients. From 20 patients, serum was obtainedat different time points at their three-monthly follow-up appointments as part of the ongoing project (PreMonitioN-study).Protein expression was determined via antibody microarray. The findings were compared to standard diagnostics.Median timepoint of analysis was 12 months (IQR: 9-13.5). The sensitivity, specificity and accuracy were 87.5%,91.67% and 90%, respectively. First preliminary data from antibody microarray analyses show promising resultsregarding test accuracy for clinical application.
P75
P75
Stratifying treatment in pancreatic cancer patients via cell-free tumor DNA (tcfDNA)
Azadeh Azizian, Alexander König, Michael Ghadimi, Jochen Geadcke
Cell-free tumor DNA (tcfDNA) represent a reliable method to monitor response to chemotherapy in stage IV pancreatic cancer patients during palliative chemotherapy. Our aim is to analyze whether tcfDNA might be also a useful tool to stratify patients’ treatment before surgery. Data of 221 patients was enrolled. tctDNA in plasma was determined using the TheraSureTM CNI Monitor. We found that tcfDNA might reliably discriminate between benign and maligne leasions and also offer some information about the tumor stage. Furthermore, CNI Scores obtained from tcfDNA during surveillance elevated when recurrence occurred.
P76
P76
The impact of sarcopenia on the risk of postoperative pancreatic fistula after pancreatoduodenectomy
Teresa Perra, Alberto Porcu
Despite advances in pancreatic surgery, postoperative pancreatic fistula (POPF) is still an important complication in patients undergoing pancreatoduodenectomy. Sarcopenia is common among these patients and a combination of objective CT measurements could be used to predict the occurrence of clinically relevant pancreatic fistula.
P77
P77
Pancreatorrhaghia in patients with complicated chronic pancreatitis
Ihor Pavlyk, Oleh Kanikovsky, Oleksandr Makhovskyi, Yuliia Punko
Aim: analyze the experience of pancreatorrhaghia in patients with CP.Materials and methods. 249 patients with CP were operated. Pancreatorrhaghia occurred in 6(2.4%), group A - 3(1.2%) - as disease manifestation, group B - 3(1.2%) - after surgery.Discussion. In group A the source of bleeding was the LPDA, 2(0.8%) had LPDA aneurysms with bleeding into the cyst, 1(0.4%) - ligature eruption a year after previously performed PDR. In group B - in 3(1.2%) patients after the Frey-Izbitsky procedure: 2(0.8%) - from anastomosis, 1(0.4%) - from pancreatopleural fistula.Conclusions. Source of pancreatorrhaghia in CP is different with individual surgical approaches.
P78
P78
Drain use in pancreatic surgery: results from an international survey among experts of the International Study Group for Pancreatic Surgery (ISGPS)
Ilaria Pergolini, Stephan Schorn, Rüdiger Göß, Alexander Novotny, Güralp O. Ceyhan, Helmut Friess, Ihsan E. Demir
With this survey we aimed to evaluate habits, experience, and opinions of experts in the field members of the International Study Group for Pancreatic Surgery (ISGPS) on the use of drains in pancreatic surgery. Forty-two surgeons (42/63, 67%) completed the survey. Around 85% of the respondents routinely employ drains and 50% of them usually remove them early within the 3rd POD. The drains management was very heterogeneously for type and number of drains, enzyme testing, cut-offs and removal schedules. Overall, among the experts who completed the survey we found no agreement on the drain management and mostly an individual approach.
P79
P79
Case report: Malignant mucinous cystic neoplasm of pancreas
Veronika Rozhkova
A 54-year-old woman was presented with middle pain in upper abdomen. In 1987 cystenterostomy was performed. CT scan of the abdomen showed multilocular solid-cystic malignant formation of the tail of the pancreas. She underwent RAMPS posterior with resection of duodenojejunal junction, wedge resection of stomach, cholecystectomy and external biliary drainage via c-tube. Postoperative histological examination revealed mucinous cystic neoplasm associated with moderately differentiated ductal adenocarcinoma of the pancreatic tale pT1b(4)pN0(0/73) L1 V0 Pn0 R0. In the postoperative period she developed pancreatic fistula grade C with delayed aortic hemorrhage grade C, which required reoperation. Patient was discharged on postoperative day 54.
P80
P80
Length of small bowel resection is not associated with postoperative immediate New Onset of Diabetes mellitus after pancreaticoduodenectomy
Tengis Tschaidse, Florian Kühn, Viktor von Ehrlich-Treuenstätt, Felix Hofmann, Jens Werner, Bernhard Renz, Matthias Ilmer
There is accumulating evidence that duodenectomy rather than pancreatic resection in Whipple procedure could be the main cause for postoperative new onset of diabetes mellitus (NODM). As the proximal small bowel plays a major role in regulating endocrine and exocrine functions, we hypothesized that the length of upper small bowel resection in Whipple procedure might negatively affect postoperative morbidity.Our results from a study cohort of 175 patients undergoing Whipple procedure indicate that the length of resected small bowel in Whipple procedure does not contribute to immediate NODM nor seems to be associated with the occurrence of major postoperative complications.
P81
P81
Body mass index (BMI) in pancreatic ductal adenocarcinoma (PDAC) is a critical factor for an altered bile duct microbiology after pancreaticoduodenectomy
Viktor von Ehrlich-Treuenstätt, Jan D'Haese, Maximilian Weniger, Markus Guba, Joachim Andrassy, Martin Angele, Jens Werner, Bernhard Renz, Matthias Ilmer
This prospective study of 200 patients investigated the effects of BMI and the bile duct (BD) microbiology on morbidity in PDAC after pancreaticoduodenectomy (PD). BMI shows as a critical factor for a higher rate of perioperative morbidity in patients undergoing surgery for PDAC of the pancreatic head. Simultaneously, OW is associated with a lower rate of NCT but shorter TTS than in NW patients. NW patients (BMI <25 kg/m2) generally have a better postoperative outcome regarding the severity of complications potentially due to a BD microbiology with lower pathogenic potential.
P82
P82
Irf3 and Irf7 are important mediators of tumor cell aggressiveness in pancreatic cancer
Lisa Fahr, Simone Benitz, Tobias Straub, Jurik Mutter, Hannah Lisiecki, Ujjwal M. Mahajan, Georg Beyer, Katja Steiger, Jörg Kleeff, Christoph W. Michalski, Julia Mayerle, Ivonne Regel
The interferon regulatory factor 3 (Irf3) and Irf7 are downstream transcription factors of the Toll-like receptor 3 (Tlr3) signaling pathway. Tlr3, Irf3 and Irf7 are highly abundant in pancreatic epithelial cells of acinar-to-ductal metaplasia (ADM) and in pancreatic cancer lesions. Our results indicate that activation of the Tlr3/Irf3/Irf7 signaling pathway in murine pancreatic cancer cells gives rise to an aggressive tumor cell phenotype, whereas a loss of Irf3/Irf7 results in diminished tumor formation.
P83
P83
Classical and basal-like pancreatic cancer lines respond differently towards epigenetic drug treatment
Quan Zhou, Svenja Pichlmeier, Tobias Straub, Anna Kirmayr, Simone Benitz, Ujjwal Mahajan, Lisa Fahr, Christoph W Michalski, Jörg Kleeff, Julia Mayerle, Ivonne Regel
Large-scale genome sequencing and gene expression studies have defined distinct PDAC subtypes reflecting tumor heterogeneity. Since they mostly share the same mutations, epigenetic modifications might contribute to the tumor heterogeneity of PDAC so it represents a promising target for new treatment strategies. Based on these aspects, we investigate whether epigenetic reprogramming of PDAC cells can be achieved by targeting histone acetylation.Our results exhibit that epigenetic modifications are differentially enriched in the classical and basal-like subtypes and determine the underlying expression of subtype-specific genes. Further approaches are needed to reveal the full potential of epigenetic drugs in reprogramming PDAC subtypes.
P84
P84
Prognostic markers for the response of nanoliposolal Irinotecan in subsequent line treament of advanced pancreatic cancer - a retrospective analysis
Marius Brunner, Lena Marie Heinrich, Alexander König, Volker Ellenrieder
Subsequent line therapy in advanced pancreatic cancer has become routine in the past years due to new drug developments. However, there are no valid prognostic markers available to predict response to subsequent line chemotherapy. In this retrospective study, we identified a significant correlation betwenn the routine CRP (C-reactive protein) value and overall survival after starting treatment with nanoliposomal-Irinotecan (nal-IRI) and 5-Fluorouracil (5-FU). THis could help making treatment decisions in advanced pancreatic cancer.
P85
P85
Multiplex IHC
Theresa Weltermann, Ahmed Alnatsha, Ivonne Regel, Christian Schulz, Julia Mayerle, Ujjwal Mukund Mahajan
We present an easily implementable platform of a fully automated analysis pipeline for multiplex immunostaining established on human pancreatic, gastric and colon cancer samples. With sequential immunohistochemistry staining, up to 15 antigens can be detected on a single tissue section. The antigen panel can be customized. For analysis, we combined the open-source software QuPath, CellProfiler, ImageJ and R to a user-friendly surface. Our pipeline enables automated extraction of cell composition, marker colocalization, distribution and tissue architecture, as well as complex neighbourhood and cluster analysis.
P86
P86
FAPI- PET CT for detecting recurrence of pancreatic cancer
Lucas Sperling, Teresa Colbatzky, Manuel Röhrich, Christin Tjaden, Nathalia Giese, Ulf Hinz, Uwe Haberkorn, Thilo Hackert, Ulrike Heger
Preliminary data on PET scan with the novel trace FAPI showed high tumor-associated tracer uptakes and image contrasts in Pancreatic cancer (PC). We analyzed diagnostic accuracy of added FAPI-PET in structured follow-up after resection. Patients underwent postoperative CT of chest and abdomen and tumor marker controls every 3 months; additional FAPI-PET was performed depending on availability. FAPI PET showed good accuracy compared to standard diagnostics for detection of recurrence. Larger cohorts and longer observation spans in this ongoing project will determine the true value of FAPI-PET in follow-up after resection of PC.
P87
P87
Precision vascular anatomy for the minimally invasive pancreatic resections
Stanislav Litkevych, Joachim Wellner, Ulrich F. Wellner, Tobias Keck
The poster demonstrates the relevant vascular anatomy for pancreatic surgery, especially in minimally invasive technique
P88
P88
Robotic segmental pancreatic resection for a central neuroendocrine tumor of the pancreas
Georg Weber, Robert Grützmann, Christian Krautz
Case report of a robotic segmental pancreatic resection for localised G1 neuroendocrine tumor in a 24 year old female patient.
P89
P89
Risk Factors for Mortality in Patients Undergoing Major Pancreatic Surgery and Influence of Surgical Expertise: Data from the German StuDoQ-/Pancreas Registry
Andreas Minh Luu, Waldemar Uhl, Orlin Belyaev, Philipp Höhn, Tim Fahlbusch
All patients undergoing pancreatic resection from 2014 – 2018 were enclosed to identify risk factors contributing to postoperative mortality. Age, high ASA-score, diabetes mellitus, severe COPD, liver cirrhosis, postpancreatic hemorrhage and insufficiency of the hepaticojejunostomy were identified as independent risk factors for mortality. We observed a significant lower mortality rate in hospitals treating more than 50 patients surgically per year.All patients undergoing pancreatic resection should be treated in a high-volume pancreatic surgery center.
P90
P90
Complication Management after Pancreatic Resection - Retrospective Analysis of Different Therapeutical Regimen for Severe Complications in a Large Volume Center
Tabea Boeckmann, Steffen Deichmann, Louisa Bolm, Rüdiger Braun, Hryhoriy Lapshyn, Ekaterina Petrova, Dirk Bausch, Tobias Keck, Ulrich Wellner, Kim Christin Honselmann
The management of severe complications after pancreatic surgery remains a clinical challenge worldwide. Completion pancreatectomy (n=38, 6%), relaparotomy without completion pancreatectomy (n=38, 6%) and interventional treatment (n=15, 2%) were compared in a patient cohort (n=91) with postoperative pancreatic fistula and/ or pancreatic hemorrhage grade B or C. Baseline and surgical characteristics were similar between groups. 90-day-mortality was significantly higher in CP patients (p=0.004), whereas median overall survival did not differ significantly (log-rank=0.077). Multivariate analysis identified a higher age at time of primary surgery and conversion as independent predictors for worse survival. Importantly, completion pancreatectomy was not associated with worse survival.
P91
P91
Orointestinal microbiome as predictor of pancreatic mass dignity and post pancreatectomy complications
Christoph Ammer-Herrmenau, Catharina Lingens, Nina Pfisterer, Albrecht Neesse
Buccal and rectal swab samples are prospectively collected to analyze the microbiome of patients undergo surgery due to a pancreatic mass. The orointestinal microbiome will be associated with the dignity and the postoperative surgery. Approximately 50 patients suffering from pancreatic cancer and 50 patients with benign cystic lesions will be recruited. Their samples will be analyzed using Oxford Nanopore Technologies (16S rRNA and metagenomics).
P92
P92
Drug resistance of different pancreatic cancer stem cell populations can be overcome by sequential chemotherapy
Lisa-Marie Philipp, Susanne Sebens
Pancreatic ductal adenocarcinoma (PDAC) shows high intratumoral heterogeneity implying the abundance of cancer stem cells (CSCs) being essential for both tumor initiation and drug resistance. Epithelial-Mesenchymal-Transition (EMT) has been linked to the acquisition of CSC properties thereby contributing to cancer heterogeneity.To understand the interplay between CSC characteristics and EMT and its impact on cancer treatment, different CSC phenotypes were identified in two PDAC cell lines and evaluated for their response towards sequential chemotherapy. We could demonstrate that compare to monotherapy, sequential therapy of distinct cytostatic drugs leads to an improved treatment response, depending on treatment sequence and CSC phenotypes.
P93
P93
Metavert, a dual inhibitor of GSK3B and HDACs, in combination with cytotoxic drugs is synergistic in human pancreatic cancer cells and organoids
Jingyu An, Hu Kai, Xu Zhou, Teresa Peccerella, Hackert Thilo, Georg Beyer, Julia Mayerle, Mouad Edderkaoui, Stephen Pandol, Springfeld Christoph, Peter Bailey, Franco Fortunato, John Neoptolemos
We identified the interaction between a novel dual inhibitor(Metavert) and currently used chemotherapeutic agents (gemcitabine, paclitaxel, 5FU, irinotecan, oxaliplatin) in 2D cell lines and 3D organoids (hPDOs) by measuring the synergy score in the dose-dependent viability assay. Also, by employing RNA sequencing to acquire the transcriptomic atlas of 17 individual organoids from primary PDAC tumors, a biomarker was validated as the most discerning candidate biomarker gene in response to Metavert.
P94
P94
Neoadjuvant chemotherapy induces GATA6-upregulation relating to molecular subtype switching and chemoresistance in pancreatic cancer
Kai Hu, Shigenori Ei, Roma Kurilov, Xu Zhou, Jingyu An, Teresa Peccerella, Peter Bailey, Christoph Springfeld, Frank Bergmann, Benedikt Brors, Franco Fortunato, Markus W Büchler, John Neoptolemos, Thilo Hackert
RNASeq and western-blotting were used to define molecular subtypes, apoptosis, and necroptosis after single-drug treatment in pancreatic ductal adenocarcinoma (PDAC) cell lines. Dose-dependent chemotherapy, in particular 5-FU, oxaliplatin and irinotecan induced GATA6-upregulation in AsPC-1 and Su86.86. Time-dependent treatment of 5-FU, oxaliplatin and paclitaxel induced GATA6-upregulation before initiating apoptosis. Furthermore, GATA6-expression validated by quantitative immunofluorescence on FFPE samples was found to be increased in post-neoadjuvant-CTx (NAC) PDACs. Contrasting to the positive prognostic role of GATA6 in chemo-naïve samples, high GATA6-expression predicts poor prognosis in post-NAC patients. Taken together, chemo-drugs induce GATA6-upregulation in PDAC, which might be associated with subtype-switching and chemoresistance.
P95
P95
Pleiotropic role of TRAIL-R4 in pancreatic cancer cells.
Sina Schubert, Doaa Tawfik, Anna Trauzold, Monika Szczepanowski, Wolfram Klapper
While the importance of TRAIL and its death receptors TRAIL-R1/-R2 in the development/progression of cancer is widely accepted, functions of TRAIL-R4 remain enigmatic. To understand its role in PDAC, we compared the expression levels of stemness- and cancer-related genes in cells with/without knockdown of TRAIL-R4 using nCounter Assays (Nanostring Technology) and verified the results by RT-PCR and western blot. Knockdown of TRAIL-R4 impacted several pathways with clear up-regulation of epithelial-to-mesenchymal transition- and stemness-related proteins and resulted in enhancement of tumorsphere formation. Our results point to crucial role of TRAIL-R4 in PDAC and suggest its inhibitory function in EMT and stemness.
P96
P96
Patient-derived Organoid based automated high-throughput pharmacotyping for treatment selection of pancreatic ductal adenocarcinoma
Lena Schütte, Jessica Merkle, Alica Beutel, Yazid Resheq, Johann Gout, Thomas Seufferlein, Alexander Kleger
Pancreatic cancer will become the second leading cancer-related death in 2030. It is known to be highly resistant to chemotherapeutics, which also results in a poor progression-free-survival rate of about 5%. Our new organoid CoreFacility established a full high-throughput drug assay from patient-derived-organoids by using an automated liquid handler to generate dose-response curves. Data were collected to set up a machine-learning library to classify drug response. In that way up to 10 drugs can be tested simultaneously in a short timeframe to help clinicians to gain a matched therapy in a clinical setting, which is associated with an elongated progression-free-survival.
P97
P97
Risk factors for pancreatic cancer in patients with new onset diabetes - systematic review and meta-analysis
Claudia Mellenthin, Vasile Balaban, Ana Dugic, Stephane Cullati, Bernhard Egger
We searched Medline, Embase & Google Scholar according to the PRISMA guidelines. We included 18 original studies examining risk factors for Pancreatic Cancer (PC) in new-onset diabetes (NOD) patients. We conducted a quality assessment and a meta-analysis of risk factors. The proportion of PC was between 0.25% and 2.7%. The overall odds ratio for NOD versus no Diabetes was 4.24 (CI 2.80-5.69). NOD is an independent risk factor for PC. Additional risk factors are age, smoking, family history of PC, history of cholecystitis/pancreatitis. Symptoms are a rapid increase in glycemia, changes in lipid metabolism, and weight loss.
P98
P98
ALDH1A3 mediates an AP-1-dependent enhancer network promoting pancreatic malignancy
Shuang Nie, Kathleen Schuck, Andre Mihaljevic, Christoph Michalski, Bo Kong
Previously we defined an aggressive pancreatic ductal adenocarcinoma (PDAC) subtype with unfavourable prognosis labelled by ALDH1A3 (aldehyde dehydrogenase 1 family member A3). We further find that ALDH1A3 controls the oncogenic activity of activator protein 1 (AP-1) in a dose-dependent manner, leading to chromatin-accessibility variation, particularly at the enhancer region. Further analysis reveals that ALDH1A3 affects particularly the nuclear levels of S-adenosylmethionine (SAM). In line, genetic ablation of Aldh1a3 compromises KrasG12D-deriven AP-1 activation and PDAC development in vivo. As such, the ALDH1A3-mediated enhancer network further unleashes the oncogenic activity of AP-1, contributing to the unfavourable tumour biology of this subtype.
P99
P99
Implications of preoperative symptoms on patient survival after pancreatoduodenectomy for pancreatic ductal adenocarcinoma - a DGAV StuDoQ|Pancreas registry study
Yannic Elser, Tabea Böckmann, Louisa Bolm, Meike Ten Winkel, Steffen Deichmann, Rüdiger Braun, Tobias Keck, Ulrich Wellner, Kim Christin Honselmann, Hryhoriy Lapshyn
This retrospective multicenter study investigated the relationship between preoperative symptoms in 2643 PDAC patients undergoing pancreatic head resection and post-surgical outcomes utilizing the German national StuDoQ|Pancreas database.Up to 90% of patients had preoperative symptoms. Recent onset diabetes and symptoms were independently associated with overall survival.
P100
P100
Pharmacological and genetic disruption of the JNK pathways cause opposing effects on pancreatic cancer cells
Jingwei Shi, Qi Kang, Xing Yang, Christoph Michalski, Marko Kornmann, Benno Traub
As promising therapeutic targets in pancreatic cancer, we targeted the c-Jun N-terminal protein kinases by genetic ablation of JNK1 and 2 as well as pharmacological targeting by using isoform-specific inhibitors. While the endogenous inhibition of the JNK2 pathway resulted in an increased oncogenic potential, the pharmacological inhibition of JNK2 suppressed pancreatic cancer cell growth through a G2-arrest. Interestingly, all determined parameters consistently showed opposing effects between genetic and pharmacological pathway ablation.
P102
P102
Neuronal glutamate promotes pancreatic cancer cell migration through neuro-cancer synapses that fuel the GRIN2D-EZH2-E2F1-RB pathway
Lei Ren, Güralp O Ceyhan, Helmut Friess, Rouzanna Istvanffy, Ihsan Ekin Demir
Pancreatic ductal adenocarcinoma (PDAC) exhibits a strong propensity to neural invasion (NI), but the molecular mechanisms of NI are unclear. Recent studies showed that central nervous system tumors like gliomas can make glutamatergic synapses with neurons, which they exploit for their growth. We explored that neurons promote the migration of PDAC towards neurons in a glutamate-fueled manner via GluN2D mediated Glutamate-NMDAR signaling, which is regulated by the upstream EZH2-E2F1-RB pathway. This molecular machinery between synapse-triggered PDAC migration represents a novel targetable pathway.
P103
P103
Proteome profiling of PDAC and specific detection of kallikrein proteases -6 and -10 by targeted and shotgun mass spectrometry
Janina Werner, Patrick Bernhard, Klemens Fröhlich, Matthias Fahrner, Johannes Eberhard, Felix Rückert, Peter Bronsert, Oliver Schilling
In PDAC, two members of the human tissue kallikrein family, KLK6 and KLK10, were shown to be significantly upregulated. We performed a combined explorative and targeted proteome study investigating FFPE tissues of PDAC, normal pancreas, and chronic pancreatitis to better understand the disease-related proteome biology. In contrast to earlier studies referring to the KLK mRNA expression, this is the first report on KLK protein detection by targeted mass spectrometry. Our explorative study revealed differentially expressed proteins for PDAC, normal pancreatic tissue and chronic pancreatitis. We describe distinct protein expression profiles in malignant pancreatic tissue as compared to benign pancreatic tissues.
P104
P104
Neuron-triggered CCL2/CCR4/p-Paxillin pathway as a novel mechanism of neural invasion in pancreatic adenocarcinoma.
Ruzanna Istvanffy, Xiaobo Wang, Linhan Ye, Lei Ren, Kalliope N. Diacopoulos, Melanie Lashinger, Hanna Alguel, Helmut Friess, Gueralp O. Cheyhan, Marina Lesina, Ekin I. Demir, Baiba Vilne
Neural invasion (NI) is an independent prognostic factor in many solid cancers, including pancreatic ductal adenocarcinoma and colorectal cancer.In the present study, we identified the neuronally triggered CCL2/CCR4/p-Paxillin pathway as a novel mechanism of neuronal invasion in a newly generated mouse model phenotypically exhibiting the pathology of NI and copying PDAC patient samples. We found that elevated p-paxillin in cancer cells and elevated CCL2 in nerves in PDAC patient samples are unfavorable prognostic markers for overall survival. Therefore, our study provides a potential strategy for therapeutic intervention.
P105
P105
Analysis of immune checkpoint regulator PD-L1 on tumor and stroma cells in pancreatic cancer
Tina Daunke, Sascha Rahn, Sandra Krüger, Daniela Wesch, Christoph Röcken, Susanne Sebens
Pancreatic ductal adenocarcinoma (PDAC) is still one of the most aggressive solid malignancies being characterized by a pronounced heterogeneous tumor stroma. Therapies targeting Programmed cell death protein 1-ligand 1 (PD-L1) showed beneficial effects in several cancers but not in PDAC. Therefore, this study aimed to elucidate the role of PD-L1 and its therapeutic targeting in tumor and stroma cell populations. In 3D cocultures of PDAC cells and macrophages induced PD-L1 expression on both cell populations was observed being consistent with PD-L1 expression in human PDAC. Investigations about effectiveness of combination therapies in coculture with CD8+ T cells are ongoing.
P106
P106
Pancreatic proteases mediate pain in pancreatic cancer
Phillip Gärtner, Okan Safak, David Jungwirth, Sergey Tokalov, Helmut Friess, Rouzanna Istvanffy, Ihsan Ekin Demir
Pain management of pancreatic cancer patients is often insufficient due to cancerous nociceptive pathways without adequate inhibition. We identified elevated proteases in pancreatic ductal adenocarcinomas (PDAC) which are associated with pain amplification through protease-activated receptors (PAR).We showed that mice bearing PDACs and treated with selective protease inhibitors display significant lower pain levels compared to an untreated control.
P107
P107
TNF? induces classical-to-basal-like subtype switch and promotes tumor progression in pancreatic cancer
Mengyu Tu, Lukas Klein, Elisa Espinet, Theodoros Georgomanolis, Friederike Penz, Laura Urbach, Florian Wegwitz, Xiaojuan Li, Kamil Bojarczuk, Philipp Ströbel, Andreas Trumpp, Argyris Papantonis, Volker Ellenrieder, Shiv Singh
The complexed tumor heterogeneity and tumor cell plasticity are major biomedical challenges in PDAC prognosis and chemoresistance. Here, we show that pro-inflammatory cytokine TNF? shapes tumor microenvironment through subtype-specific AP-1 activity and promotes PDAC progression. JUNB/AP-1 is tightly linked to the conserved classical subtype, which displays well-differentiated tumor, in association with limited TNF? expression and macrophage recruitment. However, cJUN/AP-1 is restricted to the basal-like subtype, promoting CCL2 upregulation and recruitment of TNF?-producing macrophages, which further fosters the aggressive phenotype. Furthermore, paracrine TNF? from neighboring basal-like cells can activate cJUN-CCL2 signaling in classical tumors to induce an invasive and chemoresistant phenotype.
P108
P108
Organotypic slice cultures of pancreatic ductal adenocarcinoma as preclinical model for development of personalized treatment strategies
Benjamin Heckelmann, Olha Lapshyna, Susanne Eckelmann, Louisa Bolm, Kim Honselmann, Oliver Schilling, Maren Stillger, Tobias Keck, Peter Bronsert , Matthias Brandenburger, Ulrich Wellner, Rüdiger Braun
Trying to tackle the prognosis of pancreatic ductal adenocarcinoma (PDAC), we explored organotypic slice cultures (OTSCs) as a preclinical model for prediction of treatment response. Multiple evaluation methods such as a viability assay and histopathological staining were used to determine individual response to common therapy regimens such as gemcitabine(-paclitaxel) and mFOLFIRINOX. Perspectively, OTSCs can be used to identify individual transcriptomic and proteomic profiles associated with each response and might facilitate to evaluate new therapy strategies.
P109
P109
Axon Guidance Receptor ROBO3 Modulates Subtype Identity and Prognosis via AXL-associated Inflammatory Network in Pancreatic Cancer
Niklas Krebs, Lukas Klein, Florian Wegwitz, Elisa Espinet, Carlo Maurer, Mengyu Tu, Xingbo Xu, Stefan Küffer, Andreas Trumpp, Phillip Ströbel, Rolf Brekken, Volker Ellenrieder, Shiv K. Singh
Recently, genome-wide molecular analyses have shown an altered axon guidance SLIT-ROBO signaling pathway in pancreatic cancer (PDAC). Here, we show that ROBO3 promotes the formation of a highly metastatic and chemoresistant BL subtype. Altogether, we provide a hierarchical regulatory framework in the BL subtype ofPDAC, which underlies EMT, an inflammatory stromal program, and metastaticcolonization. We show a unique receptor signaling platform that activates pSTAT3, which, in turn, promotes the BL/metastatic phenotypic state in PDAC. Thus, targeting the ROBO3-AXL-pSTAT3 regulatory network may improve response to conventionalchemotherapy and offer favorable prognosis in a selective cohort of PDAC patients.
P110
P110
Human Organoid co-culture as a model to study pancreatic fibroblast subtypes
Xing Yang, Jingwei Shi, Qi Kang, Maximilian Denzinger, Christoph Michalski, Marko Kornmann, Benno Traub
In our research, we have established an organoid-fibroblast co-culture model. Using this model, we can study the interaction between tumor cells and fibroblasts, which can help us understand the disease better.
P111
P111
Influence of microbial colonization and pancreatic pathology on outcome after pancreatic head resection
P112
P112
Allelic regulation of CK19 during maturation of pancreatic ductal cells
Jana Krüger, Markus Breunig, Meike Hohwieler, Alexander Kleger
Human pluripotent stem cells have tremendous potential to study development and disease in vitro. Here, a heterozygous CK19-mCherry reporter stem cell line was generated to investigate the role of ductal marker CK19 in pancreatic development. Interestingly, CK19 expression was detected as early as definitive endoderm stage, increasing to almost 100% positive cells in pancreatic progenitors. Intriguingly, a shift from biallelic to monoallelic expression was observed upon further maturation towards pancreatic ductal cells, resulting in only 50% of cherry-positive cells, even though all cells stained positive for CK19. This indicates allelic regulation as a potential regulator of differentiation and maturation.
P113
P113
Improving pancreatic lineage commitment of human pluripotent stem cells
Sarah Merz, Markus Breunig, Meike Hohwieler, Alexander Kleger
Pancreatic lineage commitment during embryogenesis can be mimicked by in vitro differentiation of human pluripotent stem cells to pancreatic progenitors. Most of the progenitors are biased towards the endocrine lineage and lacking the ability to differentiate towards the exocrine cells. Here, we present a systematic screen of cytokines, small molecules and growth factors to generate a more homogenous pool of pancreatic progenitors. Elevated levels of the multipotency marker Glycoprotein 2 and constantly high levels of NKX6-1/PDX1 positive cells define a population that has the potential to further develop into pancreatic exocrine and endocrine cells, in vitro and in vivo.
P114
P114
Employing endogenous human peptides to disrupt tumor-stroma crosstalk and eliminate migrating CSCs by targeting CXCR4 receptor in PDAC
Kanishka Tiwary, Anton Lahusen, Mirja Harms, Bastian Beitzinger, Roman Schmid, Syeda Inaas, Stefanie Hauff, Karolin Walter, Alexander Kleger, Mika Lindén, Thomas Seufferlein, Jan Münch, Patrick C. Hermann
The present study examines the effect of endogenous human peptides (such as EPI-X4) on patient-derived primary pancreatic cancer cells, dual culture systems with pancreatic stellate cells and establish these peptides as novel therapeutic strategy for combating the metastatic activity of pancreatic cancer.
P115
P115
Compartment specific role of Dkk3 in the carcinogenesis of Pancreatic ductal adenocarcinoma (PDAC)
Dharini Srinivasan, Frank Arnold, Johann Gout, Elodie Roger, Alexander Kleger
PDAC is one of the aggressive cancers with poor prognosis due to the lack of reliable biomarkers for early detection. In PDAC, DKK3 is identified as a factor secreted by the stromal cells in the tumour microenvironment leading to an increase in tumour aggressiveness and metastasis. Interestingly, we identified Dkk3 acting in a tumour suppressive manner at the early stage of tumor initiation in our mouse models. Specifically, it delays the acinar cells to undergo acinar-to-ductal metaplasia. Therefore we suggest that Dkk3 acts as a friend or foe in a compartment specific manner in the carcinogenesis of PDAC.
P117
P117
Experience of total pancreatectomies in a specialized center
Mariia Onyshchenko, Olexiy Dronov, Sergey Zemskov, Petro Bakunets, Yuriy Bakunets
Total pancreatectomy (TPE) has taken its rightful place in pancreatic surgery.The aim is to analyze the morbidity and mortality of patients in the postoperative period after TPE.In the Kiev Center of the Liver, Pancreas and Bile ducts surgery, 2003-2021, TPE was performed in 43 patients. TPE were divided into elective and urgent. The postoperative mortality rate after elective surgery was 5.2%. Three years survival rate -30%, five years - 10%. Median survival – 18 months.TPE is an operation of choice in a selected group of oncological patients and has an acceptable morbidity and mortality rate.
P118
P118
The impact of preoperative biliary drainage on postoperative survival in patients with malignant obstructive jaundice
Olexii Dronov, Inna Kovalska, Petro Bakunets, Yurii Bakunets, Lyudmila Levchenko, Fedir Prytkov
IntroductionThe impact of preoperative biliary drainage (PBD) on postoperative survival (PS)remains a relevant topic for discussion.AimTo evaluate the effect of PBD on PS considering on hyperbilirubinemia andpreoperative ascending cholangitis (PAC).Materials and methodsThe prospective study of 136 patients (84-PBD, 52-no PBD). PS was evaluated byKaplan-Meier method. Cox's analysis used to determine the survival prognosticfactors.ResultsThe PS of patients who received PBD was not differ-median 34 vs. 48 months,p=0.3. Cox regression showed that hyperbilirubinemia >250 µmol/L (p= 0.007),PAC (p=0.04) predicted an unfavorable prognosis for PS.ConclusionsPBD does not impair PS rate.
P119
P119
Outcome of extended resection after neoadjuvant therapy in pancreatic carcinoma
Denise Charlotte Schütte, Ulrike Heger, Ulla Klaiber, Ulf Hinz, Markus W. Büchler, Thilo Hackert
In 667 patients with locally advanced, borderline resectable and disseminated pancreatic cancer (PDAC) treated with neoadjuvant therapy, we analysed safety, feasibility and survival parameters of extended and standard resections versus exploration in our own collective. Median overall survival was significantly longer after resection, this was retained in subgroups extended and standard resections versus exploration (14 vs. 25 vs. 9 months [p<0,001]), respectively, as well as in the subgroup of n=404 non-disseminated patients (16 vs. 26 [p<0,001] and vs. 12 months [p=0,022]). Pancreas-specific complications occurred significantly more often in extended resections among non-disseminated PDAC (63,2% vs 40,9%, p<0,001).
P120
P120
Preoperative bile duct stenting reduces survival in resectable pancreatic cancer
Maximilian Weniger, Meline Böhm, Matthias Ilmer, Jens Werner, Jan D'Haese
Patients with cancer of the pancreatic head are oftentimes treated with biliary duct stenting, which might alter the pancreatic micro- and mycobiome. Up until now, it is unclear how these changes affect outcomes after surgery. Therefore, records of 167 patients were analyzed to investigate the impact of preoperative biliary duct stenting on survival after resection of pancreatic cancer. Results show that survival is better after distal pancreatectomy compared to pancreatic head resections and on multivariable analysis, presence of Candida albicans in bile correlates with reduced survival. Therefore, upfront resection without preoperative biliary drainage should be sought wherever possible.

We thank the following institutions for their support:

© 2022 Infinite Science GmbH
  • Imprint
  • Privacy Policy
  • Sitemap
Cookieeinstellungen
X

Wir verwenden Cookies

Wir nutzen Cookies auf unserer Website. Einige sind notwendig, während andere uns helfen, diese Website und Ihre Erfahrung zu verbessern.

Ich akzeptiere

Individuelle Cookie Einstellungen

Nur notwendige Cookies akzeptieren

Datenschutzerklärung Impressum

X

Datenschutzeinstellungen

Hier finden Sie eine Übersicht über alle verwendeten Cookies. Sie können Ihre Zustimmung zu ganzen Kategorien geben oder sich weitere Informationen anzeigen lassen und so nur bestimmte Cookies auswählen.

Notwendige Cookies

Diese Cookies ermöglichen grundlegende Funktionen und sind für die einwandfreie Funktion der Website erforderlich.

Cookie Informationen anzeigen

Cookie Informationen verbergen

TYPO3 System Cookies

Diese Cookies ermöglichen grundlegende Funktionen, die für die einwandfreie Nutzung der Website erforderlich sind.

Anbieter:TYPO3
Cookiename:be_*, fe_*
Laufzeit:Dauer der Session

Cookies für Externe Inhalte

Inhalte von Videoplattformen und Social Media Plattformen werden standardmäßig blockiert. Wenn Cookies von externen Medien akzeptiert werden, bedarf der Zugriff auf diese Inhalte keiner manuellen Zustimmung mehr.

Cookie Informationen anzeigen

Cookie Informationen verbergen

Twitter Timeline

Zeigt eine externe Twitter Timeline von unserem Account an.

Anbieter:Twitter Inc.
Cookiename:Twitter
Laufzeit:365 Tage
Datenschutzlink:https://twitter.com/de/privacy
Host:twitter.com

Google Analytics

Dient zur Statistik und Erfassung personenbezogener Daten inkl. Seitenaufrufprofile durch Google

Anbieter:Google Inc.
Cookiename:_gat, _ga, _gid
Laufzeit:365 Tage
Datenschutzlink:https://policies.google.com/privacy
Host:google.com

Vimeo Videos

Registriert eine eindeutige ID, um Statistiken der Videos von Vimeo, die der Benutzer gesehen hat, zu behalten.

Anbieter:Vimeo.com, Inc.
Cookiename:Vimeo
Laufzeit:365 Tage
Datenschutzlink:https://vimeo.com/privacy
Host:vimeo.com

YouTube Videos

Registriert eine eindeutige ID, um Statistiken der Videos von YouTube, die der Benutzer gesehen hat, zu behalten.

Anbieter:Google Inc.
Cookiename:YouTube
Laufzeit:365 Tage
Datenschutzlink:https://policies.google.com/privacy
Host:youtube.com, youtube-nocookie.com, google.com

Speichern

ZurückNur notwendige Cookies akzeptieren

Datenschutzerklärung Impressum

Login / Registration
 Link to registration